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ABSTRACT
Background
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Patients diagnosed
with metastatic RCC (mRCC) have shorter overall survival compared to those diagnosed at earlier
stages. Several targeted therapies, which cost from $7,000 - $16,000 per month have been
approved since 2005 to treat mRCC. In addition, there is a growing interest in the use of
cytoreductive nephrectomy (CN) with targeted therapies among mRCC patients. However, little
is known regarding the economic burden of RCC and role of CN and prescribing patterns of
targeted therapies among older mRCC patients.
Objectives
1) To assess the economic burden of RCC among older adults in the targeted therapy era
2) To compare the overall survival (OS) and total healthcare cost (THC) among older mRCC
patients receiving CN and targeted therapy versus patients receiving targeted therapy alone 3) To
describe prescribing patterns of targeted therapies and associated OS and THC among older mRCC
patients.
Methods
This dissertation was conducted using the Surveillance Epidemiology and End Results
(SEER) - Medicare linked data. For the first objective, the study included a prevalent cohort of
RCC patients from 2013, diagnosed during 2005 - 2013 and continuously enrolled in Medicare.
RCC patients were matched to non-cancer beneficiaries using propensity score matching.
Generalized linear models estimated the incremental healthcare costs. Incremental total healthcare
cost (THC) was multiplied by the estimated number of RCC patients on Medicare to calculate the
total economic burden of RCC. For the second objective, we included patients diagnosed with
xi

mRCC between 2007-2014 and compared overall survival (OS), and THC between patients who
received CN + targeted therapy and targeted therapy alone. A propensity score based inverse
probability of treatment weighting (IPTW) method was used to balance the two treatment groups.
A Cox proportional hazard model assessed the risk for death and a GLM compared healthcare
costs between the groups. For the third objective, patients with mRCC were defined as patients
who were diagnosed at stage-IV or at earlier stages but were currently using targeted therapies.
Further, we restricted our sample to patients who initiated targeted therapy. We described the
frequencies of the most common first and second line targeted therapies. We also described OS
and THC per month for clear-cell and non-clear cell mRCC for each therapy and line of therapy.
Results
The first study included 10,392 each of RCC and control patients. The average THC
associated with RCC was $7,419. The average THC was $4,584 for patients diagnosed at stage-I,
$4,727 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. The annual economic burden
of RCC on Medicare was estimated to be $1.5 billion. The second study included 471 mRCC
patients that received CN + targeted therapy or targeted therapy alone. The median OS from the
adjusted survival curves was significantly higher (p <0.0001) for CN + targeted therapy group (15
months) than the targeted therapy alone group (10 months). CN + targeted therapy group had 0.63
times the risk of death (HR = 0.63) compared to the targeted therapy alone group. The adjusted
total healthcare cost per month was $17,159 for CN + targeted therapy group and $18,120 for the
targeted therapy alone group (p = 0.4389). The third study included 915 mRCC patients with
targeted therapy prescription. Among clear cell mRCC patients, sunitinib (384, 48%) and
everolimus (101, 13%) were the top first and second line targeted therapies. Of 109 non-clear cell
patients, sunitinib (n = 35, 32%) and temsirolimus (n = 26, 24%) were the most commonly

xii

prescribed first line targeted therapies. Among patients who received multiple lines, VEGF-mTOR
was the most commonly prescribed sequence. The median OS and median monthly THC was
similar across targeted therapy sequences.
Conclusions
The economic burden of RCC varied substantially between early stage and metastatic
patients. Among mRCC patients, use of CN among targeted therapy users was associated with a
higher median OS and similar monthly THC over a lifetime. Sunitinib and everolimus were the
most common first and second line targeted therapies among mRCC patients. The descriptive
analysis suggested that OS and THC were similar across types of targeted therapy sequences.
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Chapter 1: Introduction
Renal Cell Carcinoma
Epidemiology
Renal cell carcinoma (RCC) is the most common type of kidney cancer. About 9 out of 10
kidney cancers are RCC.

1, 2

Other forms of kidney cancer include transitional cell carcinomas,

Wilms tumors, and renal sarcomas. RCC usually grows as a single tumor within a kidney, however,
sometimes multiple tumors can be found in one or both the kidneys. A very early stage RCC is
often asymptomatic but large tumors often show symptoms that include presence of blood in the
urine, lower back pain on one side, mass on the side or lower back, fatigue, loss of weight, fever,
and anemia. Subtypes of RCC include clear-cell RCC, which accounts for 70% of cases, Papillary
(10%), Chromophobe (5%) and rare types (5%) and unclassified (10%). These subtypes play an
important role in deciding treatment or in finding out if cancer might be due to inherited genetic
syndrome.1, 2
The American Cancer Society (ACS) estimated that in the U.S, in 2017, approximately
63,700 new kidney cancer cases (39,650 in men and 23,050 in women) would be diagnosed and
14,240 people (9,240 men and 5,000 women) would die from this disease.1 These numbers include
all types of kidney and renal pelvis cancers. Overall, the lifetime risk for developing kidney cancer
is about 1 in 63 (1.6%). Incidence for RCC has increased from 9 per 100,000 persons in 1990s to
15 in 2007 and leveled off in the last few years.1, 2 The median age of RCC diagnosis is 64 years
and it very uncommon among individuals aged < 45 years. Men often have a higher risk (~2 times)
for RCC than women. Other risk factors for RCC include smoking, obesity, high blood pressure,
African American and American Indian race, workplace exposure to substances such as cadmium,
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family history, certain medicines such as diuretics, an advanced kidney disease that requires
dialysis and presence of genetic conditions such as Von Hippel-Lindau (VHL) disease.1
Staging and Survival
Cancer staging indicates the extent of the disease and its prognosis. The most common
staging system for RCC is that of the American Joint Committee on Cancer (AJCC).1, 3 Stage-I
indicates that the tumor is 7 cm across or smaller, located only in the kidney and has not spread to
lymph nodes or distant organs. Stage-II indicates that the tumor is larger than 7 cm across but is
still only in the kidney. There is no spread to lymph nodes or distant organs. Stage-III indicates
that the tumor has spread to the major blood vessels – the renal vein and inferior vena cava, into
the tissue surrounding the kidney, or to nearby lymph nodes. Stage-IV indicates that the tumor has
spread outside of the kidney to the adrenal gland, to distant lymph nodes, or to other organs.
According to statistics presented by the Surveillance, Epidemiology and End Result
(SEER) program, about 65% of RCC cases are diagnosed at localized stage, 16% have
involvement of regional lymph nodes, 16% are diagnosed with distant metastasis and 3% have
unknown stage.2 Further, literature suggests that about 15%-40% of patients are diagnosed at the
metastatic stage and among those diagnosed at early stages; over 30-33% eventually progress to
metastatic stage.4, 5 The five-year survival rate for RCC patients based on data from 2007 to 2013
was 74.1%; however, it varied by cancer stage. Survival rates were 93% for localized, 63% for
regional, 38% for unknown and 12% for metastatic renal cell carcinoma (mRCC) patients.2
Treatment for Stages I-III 1
Patients with localized tumor are often treated with surgery that includes partial or radical
(complete) nephrectomy. Partial nephrectomy removes portions of a kidney while radical
nephrectomy involves complete removal of kidney. Partial nephrectomy is often the treatment of
2

choice in tumors up to 7 cm in size. Surgery may involve removal of lymph nodes near the kidney,
especially if they are enlarged. If cancer has grown into the nearby vein (stage-III), surgery is
needed to remove a tumor from the veins. Adjuvant therapy, which, includes surgery followed by
treatment with targeted therapy, chemotherapy, or radiation therapy has also been tried as another
option among Stage-III patients. So far, it has not been shown to help patients live longer. 1 There
are, however, ongoing clinical trials that are looking at adjuvant treatment for locally advanced
RCC. Patients that cannot undergo surgery because of other serious medical problems, patients
may be given local treatments such as cryotherapy, radiofrequency ablation, or arterial
embolization or radiation therapy. These options, however, are often considered as less effective
options than surgery. Active surveillance is another option for some people with small kidney
tumors. In this approach, the tumor is watched closely (with CTs or ultrasounds) and only treated
if it grows.1
Treatment for Stage IV / mRCC
Treatment among mRCC patients depends largely on the extent of tumor growth and
overall health status; however, for the most part, it involves the use of systemic therapy with
immunotherapy or targeted therapy agents.1 Before 2005, the treatment of mRCC mainly included
cytokines: high dose interleukin-2 and interferon-alpha. However, both drugs were associated with
low response rate, higher toxicity and improvement of fewer than 6-12 months in the OS.6, 7 From
2005 to 2012, the US Food and Drug Administration (FDA) approved seven targeted therapies to
treat mRCC.8-12 These therapies included vascular endothelial growth factor (VEGF) receptor
tyrosine kinase inhibitors (TKI) sorafenib, sunitinib, pazopanib, and axitinib; the mammalian
target of rapamycin inhibitors (mTOR) everolimus and temsirolimus; and the anti-VEGF
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monoclonal antibody bevacizumab. Everolimus and axitinib are approved only as second-line
treatments. From 2016, cabozantinib, lenvatinib, and nivolumab were approved for mRCC.
Details of these therapies are given in Table 1.

Table 1. FDA approved targeted therapies for metastatic Renal Cell Carcinoma
Drug

Mechanism

Line of therapy

Sorafenib
Sunitinib

FDA
approval
2005
2006

VEGF- TKI
VEGF- TKI

First & Second
First & Second

Temsirolimus

2007

mTOR

First & Second

Everolimus

2009

mTOR

Second only

bevacizumab +
interferon-alfa
Pazopanib
Axitinib
Cabozantinib

2009

Anti-VEGF

First & Second

2009
2011
2016

First & Second
Second only
First & Second

Lenvatinib

2016

VEGF-TKI
VEGF-TKI
TKI with
multiple
pathway
inhibitor
VEGF-TKI

Nivolumab

2016

PD -1

First and second

Second

Dosage Regimen
400 mg twice a day
50 mg once a day, 4 weeks
on 2 weeks off
25 mg IV infusion once
weekly.
10 mg once daily.
10 mg/kg IV every 2 weeks
+ interferon alfa
800 mg / day
5-10 mg twice a day
60 mg per day

18 mg per day with
everolimus
240 mg every 2 weeks

Sequencing of Targeted Therapies
Patients treated with first-line targeted therapy often develop resistance in 6-11 months and
as a result, need subsequent lines of therapy to control disease progression.9, 13 Several studies have
assessed the appropriate sequence of targeted therapies to improve OS. Based on previous studies,
the most common sequences in clinical practice included VEGF followed by mTOR and VEGF
followed by VEGF.14-16 Some patients with poor risk may receive mTOR as a first line followed
by VEGF. Studies which compared OS between VEGF-VEGF and VEGF-mTOR found no
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significant difference in the OS between the sequences.17, 18 The National Comprehensive Cancer
Network (NCCN) develops evidence-based guidelines to help healthcare professionals in
oncology to decide appropriate treatment strategy for cancer patients. Category-1
recommendations indicate uniform consensus about the appropriateness of intervention among
NCCN panel members based on a high-level of evidence; category-2A indicates uniform
consensus based on a lower level of evidence; category-2B indicates some consensus based on a
lower level of evidence and category-3 indicates major disagreement about the appropriateness of
the intervention.19 The NCCN guidelines during 2007-2012 included sunitinib, pazopanib, and
bevacizumab/interferon with category-1 recommendation and sorafenib with category-2A
recommendation for the first-line treatment. Recommendations for the second line therapy
included all of the above agents and everolimus. However, axitinib and everolimus have a
category-1 recommendation as second-line treatments

19-21

No recommendations were made for

the use of third-line use of targeted therapies.

Role of Cytoreductive Nephrectomy (CN)
Prior to the targeted therapy era, CN was considered as a preferred treatment option among
mRCC patients that were eligible for surgery. Two RCTs demonstrated that the use of CN in
addition to cytokine therapies resulted in improved OS by additional 6 months. 22, 23 As a result,
CN followed by interferon-alpha had level-1 evidence to treat mRCC patients. However, with the
approval of targeted therapies which were more effective than cytokine therapies, the role of CN
has been questioned. Some studies have found the use of CN decreased after 2005.24, 25 However,
a few retrospective studies conducted in the targeted therapy era suggested that CN may still play
an important role in improving OS among mRCC patients who received targeted therapies.26, 27
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Two prospective trials are also ongoing to understand the efficacy of CN among targeted therapy
users.28 However, their results may be limited based on their selection criteria and thereby not
generalizable to all patients diagnosed with mRCC.
Economic Burden of RCC
Diagnosis and treatment of RCC can impose a significant economic burden on the
healthcare system, patients, and their caregivers. Economic burden typically includes direct
medical and non-medical costs and indirect cost, which include the cost associated with
absenteeism, mortality, and loss of employment. About 46% of all RCC patients are on Medicare
making it the largest payer for RCC patients in the U.S.1, 29
According to a review published in 2010, the economic burden of RCC in the U.S ranged
from $600 million to $5.19 billion, with annual per-patient medical costs between $16,488 and
$43,805 (2009 USD).30 In 2006, the economic burden specifically among mRCC patients was
estimated to be between $107 to $556 million (2006 USD) in the US.31 In another study, the
average annual direct medical cost among older RCC patients was $11,169; and varied from
$24,694 in the initial, $6,218 in the continuous, to $26,784 in the late phase of the survival curve
among RCC patients (2009 USD).32 Further, costs among patients treated with targeted therapies
were 3-5 times higher than those for patients not treated with targeted therapy. Higher late phase
cost and high cost among targeted therapy users suggest that the burden among patients with
mRCC may increase as patients would receive more lines of therapies during to expanding
landscape of systemic therapies.

6

Rationale
A number of studies assessed the economic burden of RCC in the cytokine era. However,
only one study was conducted during the earlier years of the targeted therapy era.32 Further, costs
among patients on Medicare Part D plans were not assessed as Part D data was not available until
2007. As a result, little is known about the economic burden of RCC in the targeted therapy era.
Further, economic burden by stage at which cancer is diagnosed is not well understood. Further,
no study has projected the total economic burden to the entire Medicare population. As the
landscape of targeted therapies continues to evolve, patients are more likely to receive multiple
lines of targeted therapies than they received in the past. This would increase healthcare cost to
Medicare. On the other side, for early stage patients, use of active surveillance, advanced imaging,
and minimally invasive surgical techniques may result in cost savings. As a result, it is important
to understand the economic burden of RCC in the targeted therapy era.
Among mRCC patients, the role of CN was well established before targeted therapies were
approved. However, few studies have assessed the effects of CN and targeted therapy on OS of
mRCC patients in the targeted therapy era.26, 27 Further, none of the studies were specifically
conducted among older adults. The socioeconomic and clinical predictors of CN and/or targeted
therapy use among Medicare patients and the healthcare costs associated with the use of CN and
targeted therapy are not well understood among Medicare patients. Examination of OS and
healthcare cost would provide real-world evidence on the use of CN and targeted therapy among
older adults.
As the landscape of targeted therapies expanded from 2005 - 2012, a number of studies
assessed sequencing of targeted therapies and its association with the OS. 14-16 However, none of
the studies assessed prescribing patterns among older mRCC patients. Availability of several
7

targeted therapies, patients’ and physicians’ preferences, older age, frailty, drug interactions and
comorbidities may complicate prescribing patterns of targeted therapies among older adults.
Therefore, one of the aims of this dissertation is to describe prescribing patterns, OS and healthcare
costs among mRCC patients on targeted therapies.
Specific Aims
This dissertation included three specific aims, which formed the basis for three research studies.
These studies and research questions that they address are listed below.
Study 1: Economic Burden of Renal Cell Carcinoma among Older Adults in the Targeted
Therapy Era.
Research Questions:
1. What is the average direct healthcare cost associated with RCC in a given year?
2. What is the total economic burden of RCC on Medicare?
3. How do the average cost and the total economic burden vary by stage at diagnosis?
4. What are the most common drivers of total healthcare cost?
Study 2: Utilization of Targeted Therapy and Cytoreductive Nephrectomy among Older
Adults with Metastatic Renal Cell Carcinoma: Analysis of Survival and Healthcare Costs
Research Questions:
1. What is the prevalence of targeted therapy and cytoreductive nephrectomy use among
older mRCC patients?
2. What are the sociodemographic and clinical predictors of mRCC patients receiving CN
and /or targeted therapy?
8

3. Is there a difference in the overall survival between mRCC patients who received CN and
targeted therapy versus targeted therapy alone?
4. Is there a difference in the total healthcare cost between mRCC patients who received CN
and targeted therapy versus targeted therapy alone?
Study 3: Prescribing Patterns of Targeted Therapies, Overall Survival, and Total Healthcare
Cost among Older Adults with Metastatic Renal Cell Carcinoma in the U.S
Research Questions:
1. What proportion of mRCC patients received two or more lines of targeted therapies?
2. What were the most common targeted therapy sequences among mRCC patients?
3. How did overall survival vary by the targeted therapy sequences?
4. How did total healthcare costs vary by the targeted therapy sequences?

9
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Chapter 2
Study 1: Economic Burden of Renal Cell Carcinoma among Older Adults in the Targeted
Therapy Era
ABSTRACT
Objective
To assess the economic burden of renal cell carcinoma (RCC) among older adults on Medicare.
Methods
The study analyzed the Surveillance Epidemiology and End Result - Medicare linked data. We
included a prevalent cohort of RCC patients from 2013, diagnosed during 2005 - 2013, and
continuously enrolled in Medicare. RCC patients were matched to non-cancer beneficiaries using
propensity score matching. Healthcare costs were calculated using a phase-based approach, which
classified patients into early, continuing and late phases of care. Generalized linear models
estimated average annual incremental costs. Incremental total healthcare cost (THC) was
multiplied by the estimated number of RCC patients on Medicare to calculate the total economic
burden of RCC.
Results
The study included 10,392 each of RCC and control patients. The average annual THC associated
with RCC was $7,419 for all phases, $22,752 for initial phase, $4,860 for continuing phase and
$13,232 for the late phase of care. The average THC was $4,584 for patients diagnosed at stage-I,
$4,7272 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. For patients diagnosed at
stages I-III, hospital cost (approximately $1,500 - $3,400) was the largest component of THC. For
stage-IV patients, prescription drug cost ($11,747) was the largest component of THC. The annual
economic burden of RCC on Medicare was estimated to be $1.51 billion.
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Conclusions
Economic burden of RCC varied substantially between early stage and metastatic patients. This
research provided a baseline that can be used to assess the economic value of emerging therapies
among older RCC patients.
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BACKGROUND
Renal cell carcinoma (RCC) is the most common type of kidney cancer. In 2017,
approximately 63,990 new kidney cancer cases would be diagnosed and 14,440 people would die
from this disease.1 The median age of RCC diagnosis is 64 years. Medicare covers about 46% of
RCC patients.2, 3 As the number of older adults continues to increase, the burden of management
of RCC on Medicare will be substantial.
Management of RCC has evolved over time. Smaller tumors (≤ 4 cm) are now typically
managed with active surveillance, cryotherapy, radiofrequency ablation or partial nephrectomy.
Patients with localized but larger tumors (≥ 4 cm) are treated with nephrectomy.2, 4, 5 Significant
changes in treatment patterns also occurred in the management of metastatic RCC (mRCC). Until
2005, systemic therapy for mRCC included the use of interleukin-2 and interferon-alfa.6, 7 From
2005, targeted therapies, which cost from $5,000 – $15,000 per month, were approved to treat
mRCC. These included sorafenib, sunitinib, and temsirolimus, pazopanib, everolimus,
bevacizumab, and axitinib.8-11 Recently, FDA approved cabozantinib in intermediate and poor risk
patients as a first line therapy12 and programmed death (PD)-1 targeted check-point inhibitor,
nivolumab as a 2nd line therapy.13 In addition, there is a great interest in the combination regimens
such as nivolumab and ipilumimab.14 Nevertheless, the costs of targeted therapies, along with the
costs of administration and management of adverse events, may result in a significant economic
burden on Medicare.
A number of studies in the past have assessed the economic burden of RCC.3,15-19 Estimates
from previous studies on the economic burden of RCC ranged from $600 million to $5.19 billion,
with annual per-patient medical costs between $11,169 and $43,805 (2009 USD). However, a
majority of studies were conducted during the cytokine therapy era. Only Shih et al. (2011)
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assessed the economic burden of RCC at the beginning of the targeted therapy era using Medicare
data from 1991 to 2005 and MarketScan claims data from 1991 to 2007.18 The average annual
direct medical cost among older RCC patients was $11,169. Further, costs among patients treated
with targeted therapies were 3-5 times higher than for patients not treated with targeted therapy.
Because Medicare Part D was not available in 2005, drug costs were assessed using Medicare
supplemental coverage data from MarkeScan. These costs may not accurately represent the burden
among all older patients on Medicare Part D plans. Additionally, a number of targeted therapies
approved since 2009 were not included in this study.18 As the landscape of targeted therapies
continues to evolve, patients are more likely to receive multiple lines of targeted therapies than
they received in the past.20 This would increase healthcare cost to Medicare. On the other side, for
early stage patients, use of active surveillance, advanced imaging, and minimally invasive surgical
techniques may result in cost savings.
The aim of this study was to assess the economic burden of RCC among older adults from
Medicare’s perspective. The study also assessed healthcare costs by types of resources used and
the stage at which cancer was diagnosed.

METHODS
Data Source
SEER-Medicare
The Surveillance Epidemiology and End Result (SEER) program, initiated by the National
Cancer Institute (NCI), collects information on cancer statistics in an effort to reduce the cancer
burden among the U.S population.21 The information collected by this population-based cancer
registry includes demographics, incident cancer diagnosis, cause of death, cancer stage, tumor
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characteristics, and surgery and radiation therapy provided during the first course of treatment. As
of 2016, SEER registries covered 28% of the U.S population.22 Medicare data provides
information on Part A (hospital), Part B (outpatient) and Part D (prescription drug) claims for
Medicare beneficiaries. SEER-Medicare links SEER and Medicare data. In order to compare
cancer patients on Medicare living in SEER regions to non-cancer patients, NCI provides a 5%
random sample of Medicare beneficiaries with no cancer from SEER regions.21
We used 2005-2013 SEER-Medicare linked data for RCC patients and a 5% random
sample of non-cancer Medicare beneficiaries for controls. The Patient Entitlement and Diagnosis
Summary File (PEDSF) was used to obtain demographics and cancer diagnosis-related
information. Resource use and cost-related information were obtained from Medicare Provider
Analysis and Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies
(HHA), hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used
to obtain inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on
hospice care utilization. The carrier file provided information on non-institutional physicianprovided services whereas the outpatient file provided information on institutional physicianprovided services. The PDE file provided data related to prescription medication use (Medicare
Part D). DME files provided data on the use of durable medical equipment while HHA files were
used to get information on services provided in patients’ homes.
Study Design and Sample Selection
The study used a prevalence-based design to quantify the economic burden of RCC in
2013. Patients diagnosed in 2013 and before (from 2005) were identified using ICD-O (v.3) code
C649 and relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318'). Healthcare costs
were examined using 2013 claims. To be included in the study, patients needed to be alive for at
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least one month in 2013. We excluded patients aged < 65 years at the time of diagnosis, diagnosed
with another cancer, diagnosed on autopsy, with cancer reported by death certificate, or enrolled
in health maintenance organizations (HMOs). Control group was assigned a random date of
pseudo-diagnosis between January 2013 to end of December 2013. Control patients aged <65 years
at the time of pseudo-diagnosis, not continuously enrolled in Medicare, or enrolled in HMOs were
excluded. Figure 1 depicts the sample selection process for the RCC and control groups.
The total healthcare cost (THC) was estimated using the phase-based approach, which
classifies patients into early, continuing and late phases of care.18, 23, 24 In this study, early phase
included patients diagnosed in 2013 who remained alive at the end of 2013. Patients who died in
2013 represented the late phase. Patients diagnosed before 2013 who remained alive at the end of
2013 represented the continuing phase. A pseudo date of diagnosis and Medicare date of death
were used to classify control patients into initial, continuing and late phases. To reduce selection
bias, RCC patients were matched in a 1:1 ratio with control patients for each phase using
propensity score matching (PSM). PSM was a two-step process. In the first step, the probability
of being diagnosed with RCC was calculated using multivariable logistic regression controlling
for age, sex, race, SEER registry, urban-rural status and NCI Comorbidity Index score. In the
second stage, patients from RCC and control groups were matched using a greedy matching
technique.25 The quality of matching was assessed by the distribution of propensity scores and
comparing standardized scores for patient characteristics before and after matching. Standardized
scores of <10% after matching indicated a good match.26, 27
Study Measures
Healthcare cost
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Since this study was conducted from Medicare’s perspective, only direct medical costs to
Medicare were included. Out of pocket costs were not included in the cost analysis. Costs were
defined as the amounts reimbursed by Medicare for each claim. Costs were calculated for each
type of resource used and aggregated to obtain THC. Incremental cost, which is the difference in
the average cost of RCC and matched control patients was the costs associated with RCC.
Incremental costs were estimated for each phase as well as for the aggregated sample.
Other variables
These variables included patient demographics, urban/rural status, geographical region
based on areas represented by SEER registry, cancer stage, histology and NCI comorbidity index.
We used the American Joint Committee on Cancer (AJCC 6th edition) criteria to classify patients
into stages I - IV and unknown stage.28
RCC prevalence/number of patients
Identifying the number of older RCC patients in the U.S was a two-step process. In the first
step, we calculated the number of older RCC patients living in areas represented by SEER
registries in 2015 (diagnosed before and during 2015) using SEER Stat software.29 In the second
step, the estimate based on SEER registries was used to derive the number of older RCC patients
in the U.S using the Projected Prevalence (ProjPrev) Software developed by the NCI.30
Statistical Analysis
We compared patient characteristics between unmatched RCC and control groups using
chi-square tests and t-tests as appropriate. After PSM, differences in characteristics were examined
using paired t-tests and McNemar tests. Incremental costs between matched groups were
calculated using generalized linear models controlling for age, sex, race, SEER registry,
urban/rural status, NCI Comorbidity Score and length of the time spent in each phase of care. The
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choice of distribution for GLMs was based on modified Park tests, while the appropriate links
were selected based on Pearson correlation tests, Pregibon link tests, and modified Hosmer and
Lemeshow tests. In cost categories with excess zeros (defined as ≥ 20%), two-part models were
used. In a two-part model, the first part calculated the probability of having a positive cost. The
second part calculated the expected mean cost. This mean cost was multiplied by the probability
calculated in the first part to estimate the mean cost for the sample. Incremental costs were
calculated between RCC and non-cancer controls for the overall sample and by cancer stage. While
calculating costs by cancer stages, we compared costs for each stage to costs for non-cancer
controls. Upon examination of the distribution of THC, we excluded observations with THC >
$400,000 (99.9th percentile) and their matched cases or controls, which were considered as
outliers. In addition, to account for the skewed distribution of cost data, we calculated confidence
intervals for mean costs using a non-parametric bootstrapping method with 1000 replications.
The total economic burden of RCC among older adults was calculated by multiplying the
average incremental THC with the estimated number of older RCC patients in the U.S. All costs
were inflated to 2015 USD using the Consumer Price Index for medical care services and medical
care commodities.31
Sensitivity Analyses
First, we included observations that were considered as outliers in the base-case scenario.
Second, since comorbidities may fall into the causal pathway between RCC diagnosis and
healthcare costs, we excluded the NCI comorbidity score from the propensity score model and reexamined incremental costs and total economic burden. Third, we excluded covariates from the
GLM model after matching RCC and control groups to calculate incremental costs. Fourth, we
used GLM models using the commonly used log link and gamma distribution instead of
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distributions and links, which were chosen based on the model fit tests. The stage of cancer in
SEER data is determined at the first cancer diagnosis. Some of the early stage patients from 20052012 may have progressed to stage-IV in 2013. Therefore, we assumed that 30% of patients
diagnosed with earlier stages prior to 2013 may have progressed to stage-IV in 2013.32-34 Under
this assumption, we recalculated the total economic burden among stage-IV and overall RCC
patients.
All statistical analyses were conducted at an alpha level of 0.05 using SAS v.9.4 (SAS
Institute Inc., Cary, NC), and STATA (version 13.0, StataCorp, College Station, TX).
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Figure 2.1. Sample selection process for Renal Cell Carcinoma and non-cancer patients in
this study
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RESULTS
Sample Characteristics
Patient characteristics for RCC and control group patients before and after matching can
be found in Table 2.1 The sample before matching included 10,408 RCC and 170,061 control
patients. Before matching, large differences were observed between characteristics of RCC and
control patients. The RCC group had a lower proportion of patients (16% vs 25%) aged > 80 years,
a higher proportion of males (56% vs 39%), and Caucasians (87% vs 83%) and a lower proportion
of patients with zero NCI comorbidity score (53% vs 70%) than control group.
The study sample after matching included 10,392 each of RCC and control patients. The
magnitude of difference observed between RCC and control groups was reduced after matching.
The average age was 74 years for RCC and 75 years for controls. RCC and control groups had a
similar proportion of males (56% vs 59%), Caucasians (87% vs 84%) and patients with zero NCI
comorbidity score (53% vs 51%). All standardized differences between matched groups, except
age, were < 10%, which indicated a good match between the two groups.
Among RCC patients, 65% were diagnosed at stage-I, 8% was diagnosed at a stage-II, 15%
were diagnosed at stage-III, and 7% were diagnosed at stage-IV. About 81% had a clear-cell
histology.
Total Healthcare Cost per patient
The annual THC per patient was $23,489 for RCC and $16,070 for the matched control
group. The incremental THC per patient was the $7,419 for all phases combined, $22,752 for the
initial phase, $4,860 for the continuing phase and the $13,232 for the late phase. In each phase, the
difference in cost between the RCC and control group was significant (p < 0.05). The THC per
patient also varied by stage at which the cancer was diagnosed. Average incremental THCs for
patients diagnosed at stages I and II were approximately $4,700 - $5,000; whereas the average
24

incremental THCs for those diagnosed at stage-III and stage-IV were $9,331 and the $31,637
respectively. The average THC for patients diagnosed at stage-IV was about 6-7 times higher than
the costs for patients diagnosed at stages I and II. For patients diagnosed at stages I - III, average
THCs and incremental costs were higher in the initial and late phases than in the continuing phase.
However, for patients diagnosed with stage-IV (mRCC), average THCs were similar across all
three phases of care while incremental THCs were higher in the initial and continuing phases than
the late phase. Details of costs for RCC and control group patients by a phase of care and stage at
diagnosis can be found in Table 2.2
Total Economic Burden of RCC on Medicare
Based on the SEER Stat analysis, there were 18,121 older RCC patients alive in areas
covered by SEER registries in 2015. The projected count of older RCC patients in the U.S.
calculated using ProjPrev was 204,256. Multiplying the incremental cost of RCC by the projected
number of RCC patients resulted in the total economic burden of $1,52 billion. To calculate
economic burden by stages, we first calculated the number of RCC patients at various stages of
diagnosis by assuming a distribution similar to SEER data. The total economic burden was
estimated to be $524 million for stage-I, $68 million for stage-II, $267 million for stage-III, $1.0
billion for stage-IV and $166 million for the unknown stage. The weighted total economic burden
of RCC was found to be $2.06 billion.
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Table 2.1 Characteristics of Renal Cell Carcinoma and non-cancer patients in this study.
Characteristics

RCC
(n = 10,408)
n, (%)

Age (mean, SD) * +
Age categories (year) *
- 65 to 69
- 70 to 74
- 75 to 79
- 80 and older
Gender (% Male) * +
Race (%) * +
- Caucasian
- Black
- Others

Non-cancer
(n = 170,061)
n, (%)

RCC
(matched)
(n = 10,392)
n, (%)

Non-cancer
(matched)
(n = 10,392)
n, (%)

Standardized
difference
after matching

73.8 (6.3)

75.5 (7.3)

73.8 (6.3)

74.9 (7.1)

0.1645

3,225 (31.0)
3,486 (33.5)
2,003 (19.2)
1,694 (16.3)
5,863 (56.3)

43,043 (25.3)
52,207 (30.7)
32,763 (19.3)
42,048 (24.7)
65,978 (38.8)

3,216 (31.0)
3,479 (33.5)
2,003 (19.3)
1,694 (16.3)
5,850 (56.3)

2,883 (27.7)
3,251 (31.3)
1,995 (19.3)
2,263 (21.8)
6,162 (59.3)

0.0705
0.0468
0.0017
0.1397
0.0608

9,000 (86.5)
815 (7.8)
593 (5.7)

140,757 (82.8)
12,063 (7.1)
17,241 (10.1)

8,989 (86.5)
812 (7.8)
591 (5.7)

8,756 (84.3)
1,013 (9.8)
623 (6.0)

0.0629
0.0680
0.0127

0.5 (1.0)

0.9 (1.4)

0.9 (1.3)

1.0 (1.4)

0.0582

5,469 (52.6)
3,685 (35.4)
1,254 (12.1)

11,9240 (70.1)
41,956 (24.7)
8,865 (5.2)

5,468 (52.6)
3,682 (35.4)
1,242 (11.9)

5,283 (50.8)
3,725 (35.8)
1,384 (13.3)

0.0358
0.0086
0.0413

5,295 (50.9)
3,161 (30.4)
683 (6.6)
1,018 (9.8)
251 (2.4)

87,713 (51.6)
51,905 (30.5)
10,902 (6.4)
15,834 (9.3)
3,707 (2.2)

5,289 (50.9)
3,153 (30.4)
682 (6.6)
1,017 (9.8)
251 (2.4)

4,856 (46.7)
3,289 (31.6)
822 (7.9)
1,172 (11.3)
253 (2.4)

0.0830
0.0280
0.0520
0.0483
0.0013

2,042 (19.6)
2,823 (27.1)
1,246 (12.0)
4,297 (41.3)

33,885 (19.9)
40,345 (23.7)
19,078 (11.2)
76,753 (45.1)

2,040 (19.6)
2,818 (27.1)
1,245 (12.0)
4,289 (41.3)

2,076 (20.0)
2,743 (26.4)
1,242 (12.0)
4,331 (41.7)

0.0087
0.0163
0.0001
0.0082

1,779 (17.1)
7,806 (75.0)
823 (7.9)

24,580 (14.5)
138,112 (81.2)
7,369 (4.3)

1,778 (17.1)
7,794 (75.0)
820 (7.9)

1,777 (17.1)
7,794 (75.0)
821 (7.9)

NA

6,720 (64.6)
784 (7.5)
1554 (14.9)
756 (7.3)
594 (5.7)

NA

6,710 (64.6)
782 (7.5)
1,551 (14.9)
755 (7.3)
594 (5.7)

NA

NA

8,455 (81.2)
1,953 (18.8)

NA

8,443 (81.3)
1,949 (18.8)

NA

NA

+

NCI Comorbidity Index
Score (mean, SD) * +
NCI Comorbidity Index
Score categories * +
-0
- 1 to 2
- 3 or more
Urban /Rural (%)
- Big Metro
- Metro
- Urban
- Less urban
- Rural
SEER region *
- North East
- South
- North Central
- West
Phase of Care
- Initial Phase
- Continuing Phase
- Late Phase
Cancer Stage
- Stage I
- Stage II
- Stage III
- Stage IV
- Unknown
Histology
- Clear cell
- Non-clear cell

Note: NA: not applicable; * Difference was statistically significant (p <0.05) before matching; +: difference was
statistically significant after matching
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Table 2.2 Annual total healthcare cost associated with Renal Cell Carcinoma by disease
phase and by stage at which cancer was diagnosed
Cancer stage at
diagnosis

RCC
(US $)
(mean, 95%CI)

Matched Non-Cancer
(US $)
(mean, 95%CI)

Incremental Cost
(US $)
(mean, 95%CI)

Any Stage (n = 20,784)
All phases

23,489 (22,805 - 24,174)

16,070 (15,507 - 16,633)

7,419 (6,553- 8,285)*

Initial
Continuing
Late phase

32,669 (31,109 - 34,229)
18,939 (18,226 - 19,652)
54,983 (51,790 - 58,176)

9,917 (8,911 - 10,923)
14,078 (13,525 - 14,631)
41,750 (38,737 - 44,764)

22,752 (20,875 - 24,629)*
4,860 (3,965 - 5,756)*
13,232 (9,015 - 17,450)*

All phases
Initial
Continuing
Late phase
Stage - II (n = 11,174)

20,528 (19,749 - 21,306)
29,073 (27,113 - 31,033)
17,210 (16,408 - 18,012)
52,314 (46,565 - 58,063)

15,944 (15,385 - 16,504)
9,942 (8,925 - 10,959)
14,150 (13,574 - 14,725)
43,006 (39,798 - 46,214)

4,584 (3,652 - 5,515)*
19,131 (16,905 - 21,356)*
3,060 (2,044 - 4,077)*
9,307 (2,755 - 15,860)*

All phases
Initial
Continuing
Late phase
Stage - III (n = 11,943)

20,671 (18,407 - 22,936)
33,417 (26,976 - 39,859)
16,403 (14,107 - 18,699)
52,068 (37,575 - 66,560)

15,944 (15,385 - 16,504)
9,926 (8,922 - 10,930)
14,226 (13,660 - 14,793)
43,196 (39,847 - 46,545)

4,727 (2,418 - 7,037)*
23,491 (17,112 - 29,870)*
2,177 (-208 - 4,561)
6,398 (-6,125 - 23,868)

All phases
Initial
Continuing
Late
Stage- IV (n = 11,147)

25,275 (23,524 - 27,027)
36,489 (31,738 - 41,241)
20,946 (19,038 - 22,854)
57,923 (50,237 - 65,610)

15,944 (15,385 - 16,504)
9,879 (8,874 - 10,884)
14,190 (13,624 - 14,756)
42,966 (39,752 - 46,181)

9,331 (7,505 - 11,157)*
26,610 (21,756 - 31,464)*
6,756 (4,783 - 8,729)*
14,957 (6,701 - 23,213)*

All phases

47,581 (44,217 - 50,946)

15,944 (15,385 - 16,504)

31,637 (28,220 - 35,054)*

Initial

50,805 (44,477 - 57,133)

9,862 (8,892 - 10,832)

40,943 (34,530 - 45,357)*

Continuing
Late

46,546 (40,344 - 52,749)
62,008 (55,880 - 68,135)

14,250 (13,678 - 14,823)
41,647 (38,500 - 44,795)

32,296 (26,064 - 38,528)*
20,360 (13,571 - 27,150)*

Stage- I (n = 17,102)

Stage- Unknown (n = 10,986)
All phases

27,579 (24,562 - 30,597)

15,944 (15,385 - 16,504)

11,635 (8,559 - 14,712)*

Initial

35,026 (26,059 - 43,992)

10,014 (8,953 - 11,076)

25,011 (15,908 - 34,115)*

Continuing

22,971 (19,534 - 26,408)

14,258 (13,691 - 14,825)

8,713 (5,229 - 12,198)*

Late

59,415 (46,816 - 72,013)

42,398 (39,238 - 45,557)

17,017 (4,309 - 29,725)*

* statistically significant difference (p-value < 0.05)
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Healthcare Costs by Types of Services Used
RCC patients had significantly higher costs than controls for all types of resources used
except for DME and SNF. For RCC patients, costs related to hospitalizations ($2,282 per patient),
hospital outpatient use ($1,497 per patient) and physician-provided services ($ 1,544 per patient)
were the top three drivers of THC.
Among stage-I RCC patients, the cost associated with hospital use, outpatient services,
physician-provided services, prescription drugs and hospice care services were significantly (pvalue <0.05) higher than control group patients. Costs associated with hospital use, outpatient
services and physician provided care were the top three drivers of THC. A similar pattern was
observed for stage-II and stage-III patients. However, THC incurred among patients with stage III
were ~ 2 times the costs for stages I and II. For stages, I - III, costs associated with hospice care,
DME, SNF and home health services did not differ significantly from controls. Patients diagnosed
at stage-IV (mRCC) exhibited a different distribution of cost drivers compared to patients
diagnosed at earlier stages. For patients diagnosed at stage-IV, incremental costs were ~ 9 times
higher than patients from stages I and II and ~ 4 times higher than stage-III patients. For mRCC
patients, prescription drug cost ($11,747) was the largest component of THC. Unlike patients from
earlier stages, stage-IV patients had significantly (p<0.05) higher home health and hospice care
costs than control group patients. Details regarding costs by types of resources used and cancer
stages are described in Table 2.3

28

Table 2.3 Healthcare cost by types of resources used and cancer stage at diagnosis
RCC
(mean, 95%CI)

Matched Non-Cancer
(mean, 95%CI)

Incremental Cost
(mean, 95%CI)

Any Stage (n = 20,784)
Total
Hospital
ED
Skilled nursing facility
Outpatient services
Physician services
Prescription drugs
DME
Hospice care
Home health
Stage - I (n = 17,102)
Total
Hospital
ED
Skilled nursing facility
Outpatient services
Physician services
Prescription drugs
DME
Hospice care
Home health
Stage- II (n = 11,174)

23,489 (23,141 - 24,511)
4,830 (4,564 - 5,095)
4,709 (4,455 - 4,964)
1,503 (1,372 - 1,634)
3,053 (2,902 - 3,204)
4,419 (4,288 - 4,551)
3,817 (3,538 - 4,097)
232 (215 - 250)
723 (627 - 818)
818 (771 - 866)

16,070 (15,178 - 16,289)
2,548 (2,320 - 2,776)
3,899 (3,648 - 4,150)
1,405 (1,278 - 1,532)
1,556 (1,469 - 1,644)
2,875 (2,801 - 2,976)
2,169 (2,067 - 2,272)
247 (225 - 268)
551 (469 - 634)
691 (645 - 737)

7,419 (6,553 - 8,285)*
2,282 (1,929 - 2,634)*
811 (461 - 1,161)*
98 (-80 - 276)
1,497 (1,327 - 1,666)*
1,544 (1,385 - 1,704)*
1,648 (1,352 - 1,944)*
-14 (-38 - 10)
172 (51 - 292)*
127 (63 - 192)*

20,528 (19,749 - 21,306)
4,417 (4,096 - 4,738)
4,204 (3,892 - 4,516)
1,356 (1,202 - 1,510)
2,710 (2,535 - 2,885)
3,987 (3,849 - 4,125)
2,458 (2,299 - 2,617)
223 (205 - 242)
393 (309 - 477)
746 (690 - 803)

15,944 (15,385 - 16,504)
2,543 (2,316 - 2,770)
3,855 (3,607 - 4,103)
1,411 (1,284 - 1,538)
1,561 (1,473 - 1,649)
2,873 (2,786 - 2,961)
2,279 (2,160 - 2,398)
246 (225 - 268)
580 (493 - 667)
695 (648 - 741)

4,584 (3,652 - 5,515)*
1,917 (1,532 - 2,301)*
350 (-33 - 732)
-55 (-251 - 142)
1,149 (955 - 1,343)*
1,114 (949 - 1,278)*
179 (-19 - 377)
-23 (-49 - 3)
-187 (-304, -69)*
52 (-20 - 123)

Total
20,671 (18,407 - 22,936)
Hospital
4,128 (3,313 - 4,943)
ED
4,390 (3,304 - 5,478)
Skilled nursing facility
1,267 (827 - 1,707)
Outpatient services
2,394 (1,950 - 2,838)
Physician services
3,830 (3,409 - 4,252)
Prescription drugs
3,522 (2,456 - 4,588)
DME
256 (167 - 343)
Hospice care
701 (350 - 1052)
Home health
763 (602 - 8923)
Stage- III (n = 11,943)
Total
25,275 (23,524 - 27,027)
Hospital
5,896 (5,141 - 6,652)
ED
4,733 (4,099 - 5,364)
Skilled nursing facility
1,323 (1,036 - 1,610)
Outpatient services
3,387 (2,991 - 3,784)
Physician services
4,982 (4,568 - 5,396)
Prescription drugs
4,330 (3,503 - 5,158)
DME
213 (176 - 249)
Hospice care
821 (552 - 1,089)
Home health
909 (782 - 1,036)
* Statistically significant differences, p < 0.05

15,944 (15,385 - 16,504)
2,543(2,316 - 2,770)
3,855 (3,607 - 4,103)
1,411 (1,284 - 1,538)
1,561 (1,473 - 1,649)
2,873 (2,786 - 2,961)
2,279 (2,160 - 2,398)
246 (225 - 268)
580 (493 - 667)
695 (648 - 741)

4,727 (2,418 - 7,037)*
1,585 (747 - 2,424)*
536 (-573 - 1,646)
-144 (-600 - 313)
833 (381 - 1,825)*
957 (492 - 1,360)*
1,243 (183 - 2,304)
9 (-81 - 99)
121 (-238 - 480)
68 (-98 - 234)

15,944 (15,385 - 16,504)
2,543 (2,316 - 2,770)
3,855 (3,607 - 4,103)
1,411 (1,284 - 1,538)
1,561 (1,473 - 1,649)
2,873 (2,786 - 2,961)
2,279 (2,160 - 2,398)
246 (225 - 268)
580 (493 - 667)
695 (648 - 741)

9,331 (7,505 - 11,157)*
3,353 (2,564 - 4,142)*
878 (183 - 1,574)*
-88 (-405 - 229)
1,826 (1,424 - 2,228)*
2,109 (1,686 - 2,532)*
2,052 (1,218 - 2,886)*
-34 (-73 - 5)
241 (-38 - 519)
215 (80 - 349)*
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Table 2.3 (continued)
RCC
(mean, 95%CI)
Stage- IV (n = 11,147)
Total
47,581 (44,217 - 50,946)
Hospital
5,574 (4,586 - 6,562)
ED
7,532 (6,490 - 8,574)
Skilled nursing facility
2,266 (1,689 - 2,842)
Outpatient services
6,685 (5,840 - 7,530)
Physician services
8,061 (7,306 - 8,816)
Prescription drugs
14,026 (11,530 - 16,522)
DME
279 (200 - 357)
Hospice care
2,457 (1,877 - 3,036)
Home health
1,374 (990 - 1,387)
Stage-Unknown (n = 10,986)
Total
27,579 (24,562 - 30,597)
Hospital
4,259 (3,172 - 5,347)
ED
6,323 (5,237 - 7,409)
Skilled nursing facility
2,614 (1,936 - 3,291)
Outpatient services
3,002 (2,470 - 3,534)
Physician services
4,506 (4,046 - 4,967)
Prescription drugs
3,865 (2,573 - 5,157)
DME
301 (217 - 384)
Hospice care
1,337 (834 - 1,839)
Home health
849 (661 - 1,037)
* Statistically significant difference, p < 0.05
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Matched Non-Cancer
(mean, 95%CI)

Incremental Cost
(mean, 95%CI)

15,944 (15,385 - 16,504)
2,543 (2,316 - 2,770)
3,855 (3,607 - 4,103)
1,411 (1,284 - 1,538)
1,561 (1,473 - 1,649)
2,873 (2,786 - 2,961)
2,279 (2,160 - 2,398)
246 (225 - 268)
580 (493 - 667)
695 (648 - 741)

31,637 (28,220 - 35,054)*
3,031 (2,009 - 4,053)*
3,677 (2,591 - 4,764)*
855 (274 - 1,435)*
5,124 (4,280 - 5,968)*
5,188 (4,422 - 5,953)*
11,747 (9,258 - 14,237)*
32 (-46 - 111)
1,877 (1,298 - 2,455)*
680 (448 - 912)*

15,944 (15,385 - 16,504)
2,543(2,316 - 2,770)
3,855 (3,607 - 4,103)
1,411 (1,284 - 1,538)
1,561 (1,473 - 1,649)
2,873 (2,786 - 2,961)
2,279 (2,160 - 2,398)
246 (225 - 268)
580 (493 - 667)
695 (648 - 741)

11,635 (8,559 - 14,712)*
1,716 (598 - 2,835)*
2,468 (1,352 - 3,585)*
1,203 (514 - 1,892)*
1,441 (903 - 1,979)*
1,633 (1,165 - 1,984)*
1,586 (278 - 2,895)*
54 (-32 - 140)
757 (251 - 1,262)*
155 (-41 - 350)

Sensitivity Analyses
The average THC changed by only a small magnitude (less than 1 to 2%) in the unadjusted
analysis and after including outliers. When NCI-comorbidity score was excluded from the
propensity score model, the incremental cost per person increased by 45% from $7,419 to $10,770.
The total economic burden on Medicare increased from $1.5 billion to $1.8 billion. The THC for
mRCC increased by 10%. The use of log link and gamma distribution in a GLM resulted in a 4%
increase in the average THC and total economic burden on Medicare. Under the assumption that
about 30% of patients diagnosed before 2013 at earlier stages progressed to a metastatic stage, the
estimated economic burden of RCC was $3.3 billion and among metastatic patients was $2.5
billion. Details regarding sensitivity analyses are described in Table 2.4

31

Table 2.4 Results from sensitivity analyses
Incremental cost per patient (US $)

Total economic burden (US $)

Any
stage

Change from
base case

StageIV

Change
from base
case

Any stage

Change from
base case

Stage-IV

Change
from base
case

Base case

7,419

NA

31,637

NA

1.51 billion

NA

1.03 billion

NA

Including potential outliers

7,330

-1.20%

31,458

-0.6%

1.50 billion

-1.20%

1.03 billion

-0.6%

Excluding NCI comorbidity
index score from matching

10,770

+ 45.17%

34,880

+10.25%

2.20 billion

+ 45%

1.14 billion

+10.25%

Excluding covariates from
the regression after matching

7,274

-1.95%

31,013

-1.97%

1.49 billion

-1.95%

1.01 billion

-1.97%

GLM with log link and
Gamma distribution

7,739

+4.31%

31,235

-1.27%

1.58 billion

+4.31%

1.02 billion

-1.27%

Assume that 30% from
earlier stages and diagnosed
before 2013 may have
reached to advanced stage in
2013 **

7,419

NA

31,637

NA

3.34 billion

+120.39%

2.53 billion

+145.14%

NA: not applicable, ** average costs were considered same as main analysis but the number of RCC patients varied.
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DISCUSSION
This study assessed the economic burden of RCC from Medicare’s perspective. We used
the most recent SEER-Medicare data to reflect the economic burden in the later part of the targeted
therapy era (2009-2013). This was also the first study among older adults, in this era, to assess
drivers of healthcare costs for patients diagnosed at different stages. The average THC associated
with RCC was $7,419 while the total economic burden was estimated to be $1.52 billion. Due to
a higher prevalence of patients diagnosed at stage-I, costs associated with stage-I were the largest
component of the total economic burden. However, in terms of average THC, patients diagnosed
at stage-IV had the highest costs compared with patients diagnosed at earlier stages.
The average THC estimate from our study was similar, although slightly lower than the
estimate of $11,169 from a study by Shih et al. Some methodological differences may explain
slightly lower costs in our study. Shih et al. used frequency matching to match RCC and control
patients on patient demographics; while we used propensity scores calculated using patient
demographics and NCI comorbidity index. In a sensitivity analysis, matching only on
demographics resulted in a similar cost estimate ($10,770) than the estimate from Shih et al.18
The total economic burden of RCC (estimated at $1.5 - $3 billion) in our study was lower
than the economic burden of RCC projected by Mariotto et al ($4 - $6 billion) in the cytokine era.17
Several reasons could explain the differences. First, we included only the most common histologies
of RCC, while Mariotto et al estimated costs for all forms of kidney cancers. Second, we used
PSM where propensity scores were based on demographics and NCI comorbidity index as opposed
to matching only on age and gender. Third, several changes occurred in the management of RCC
over the last decade. While approval of several targeted therapies may have resulted in an increase
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in THC for stage-IV patients, uptake of less invasive surgical procedures and active surveillance
among early stage patients could have resulted in lower healthcare costs.
The pattern of THC by phases of care was similar to previous studies. THC was highest in
the initial phase during which patients undergo screening, receive aggressive cancer-related
treatment and require monitoring and treatment of adverse events and complications. THC was
lowest in the continuing phase, a phase where patients often have a remission and require minimal
follow-up care. THC in the late phase was higher than the continuing phase but lower than the
initial phase of care. 18, 23 Other Studies published using a phase of care approach have found that
THC was highest in the late phase of care. A different pattern of THC for the late phase of care in
our study could be due matching on comorbidities and/or differences in the operational definition
of the phase of care. Because stage-IV patients have a shorter survival compared to patients
diagnosed at earlier stages, their costs were similar across all three phases.
In our study, the costs among mRCC patients were about 9 times higher than patients
diagnosed at stages- I and II. In addition, the average cost for stage-IV patients was approximately
$28,000 more than the average cost for early stage patients. In contrast, during the cytokine era,
Hollenbeak et al. found that 1-year cost among patients with distant metastasis was $4,482 higher
(2 times higher) than costs among patients with localized disease3 and Lang et al. estimated that
the average cost for metastatic patients ($26,573) was lower than the average cost for localized
disease ($36,968), which was surprising considering the aggressive treatment given among
patients with the metastatic stage.16 Our findings suggest that although the life expectancy among
mRCC patients increased in the targeted therapy era, it also resulted in higher costs for stage-IV
patients. For patients diagnosed at stages-I to III, hospital cost was the largest component (~ 40%)
of THC. Higher costs related to hospital use may indicate the use of partial or complete
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nephrectomy, laparoscopic surgery and local therapies such as radiofrequency ablation which are
primarily used to treat early stage, localized tumor and require hospitalization. Services provided
by physicians and other healthcare professionals in hospitals and noninstitutional physician offices
were the next largest components (5% each) of THC for these patients. Smaller or non-significant
differences in the costs for the use of ED, DME, prescription drugs, hospice care, and home health
services suggested that patients diagnosed at stages I and II may use these services no more often
than matched non-cancer patients. THC among stage-III patients was about two times higher than
costs for stages-I and II, which could be due to an advanced form of the disease and relatively
aggressive form of treatment. In contrast to patients diagnosed at stage-I and II, prescription drug
costs among those diagnosed at stage-III was significantly higher than control patients. This could
be due to the use of systemic therapy in patients with recurrent disease or adjuvant use after
nephrectomy. For stage-IV patients, prescription drug costs accounted for 36% of THC, which
suggest the use of high-cost targeted therapies and medications given to control complications
arising at the site of metastasis (eg. bisphosphonates for bone metastases). In addition to
prescription drugs, costs associated with ED use were substantially high among mRCC patients
and accounted for 12% of THC. Costs associated with hospice care and skilled nursing home
facility use were much higher for mRCC patients than patients with earlier stages, which suggests
the extensive use of nursing and palliative care among stage-IV patients.
This study has several limitations. We used PSM to reduce selection bias and make RCC
and control groups similar in patient characteristics. However, we could not match on factors that
were not observed in the SEER-Medicare data such as performance status. Second, while
projecting the total economic burden to the entire Medicare population of age ≥ 65 years, we
assumed that patients on managed care plans have the same costs as patients from fee-for service
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(FFS) plans. While it was necessary to exclude patients from managed care plans due to
unavailability of their Part A and Part B claims in the SEER-Medicare data, average costs among
managed care patients may differ from patients on FFS plans. This may result in under or overestimation of the total economic burden. Due to unavailability of the data after 2013, the study did
not include newer targeted therapies such as cabozantinib, approved in 2016. The SEER data
measures cancer stage only at the time of first cancer diagnosis. Hence, the prevalence of RCC by
stage was calculated based on the initial staging information, which may not be the most recent
staging information. According to the literature about 30-33% of patients diagnosed at earlier
stages eventually progress to the metastatic stage.32,
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It is, therefore, possible that we

underestimated prevalence and total economic burden of mRCC. Lastly, the use of administrative
claims and registry data are subject to miscoding errors.
Despite these limitations, our study provided important information on the economic
burden of RCC and drivers of the THC for patients diagnosed at various stages. Several targeted
and immunotherapies have been approved recently to treat mRCC. In addition, targeted therapies
are currently being studied among locally advanced (stage-III) patients as adjuvant therapies. This
study may provide a baseline that can be used to evaluate the value of emerging therapies among
older RCC patients.
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Appendix for study 1
Appendix 2.1 Characteristics of Renal Cell Carcinoma and non-cancer patients before and
after propensity score matching - all phases combined
Characteristic

RCC
(n =
10,408)

Noncancer
(n =
170,061)

Standardize
d differences
before
matching

RCC
(matched)
(n =
10,397)

Non-cancer
(matched)
(n = 10,397)

Age at diagnosis
73.8 (6.3) 75.5 (7.3)
0.2872
Age categories (year) * +
- 65 to 69
31.0
25.3
0.1264
- 70 to 75
33.5
30.7
0.0599
- 76 to 80
19.2
19.3
0.0005
- > than 80
16.3
24.7
0.2104
Gender (% Male)
56.3
38.8
0.3567
Race (%)
- Caucasian
86.5
82.8
0.1028
- Black
7.8
7.1
0.0281
- Others
5.7
10.1
0.1650
CCI (mean)
0.5 (1.0)
0.9 (1.4)
0.3654
Urban /Rural (%)
- Big Metro
50.9
51.6
0.0141
- Metro
30.4
30.5
0.0033
- Urban
6.6
6.4
0.0061
- Less urban
9.8
9.3
0.0160
- Rural
2.4
2.2
0.0155
Registry (%)
- S. Francisco
3.1
3.8
0.0408
- Connecticut
5.6
5.7
0.0025
- Detroit
5.5
5.5
0.0031
- Hawaii
1.2
1.3
0.0114
- Iowa
6.4
5.7
0.0286
- N Mexico
2.7
2.8
0.0114
- Seattle
5.3
5.4
0.0038
- Utah
1.9
2.2
0.0186
- Atlanta
2.6
2.8
0.0097
- San Jose
2.3
2.6
0.0193
- Los Angeles
6.3
7.5
0.0436
- Greater Cali
18.5
19.5
0.0264
- Kentucky
8.2
6.7
0.0572
- Louisiana
7.7
5.8
0.0755
- New Jersey
14
14.3
0.0071
- Georgia
8.6
8.4
0.0058
NOTE: Values in bold indicate reduction in standardized differences

73.8 (6.3)

74.9 (7.1)

0.1645

31.0
33.5
19.3
16.3
56.3

27.7
31.3
19.3
21.8
59.3

0.0705
0.0468
0.0017
0.1397
0.0608

86.5
7.8
5.7
0.9 (1.3)

84.3
9.8
6.0
1.0 (1.4)

0.0629
0.0680
0.0127
0.0582

50.9
30.4
6.6
9.8
2.4

46.7
31.6
7.9
11.3
2.4

0.0830
0.0280
0.0520
0.0483
0.0013

3.1
5.6
5.5
1.2
6.4
2.7
5.3
1.9
2.6
2.3
6.3
18.5
8.2
7.7
14.0
8.6

1.9
5.7
5.7
1.6
6.3
3.8
4.5
1.8
1.3
3.4
6.0
18.7
7.3
10.5
14.3
7.3

0.0755
0.0029
0.0058
0.0358
0.0067
0.0663
0.0393
0.0100
0.0941
0.0641
0.0132
0.0054
0.0367
0.0990
0.0080
0.0469
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Standardize
d differences
after (1:1)
matching

Appendix -2.2 Characteristics of Renal Cell Carcinoma and non-cancer patients before and
after propensity score matching - initial phase
Characteristic

RCC
(N =
10,408)

Non-cancer
(N =
170,061)

Standardized
differences
before
matching
0.2872

RCC
(matched)
(N = 1,777)

Non-cancer
(matched)
(N = 1,777)

Age at diagnosis
73.8 (6.6)
75.9 (7.9)
73.8 (6.6)
Age categories
- 65 to 69
31.3
25.5
0.1283
31.3
- 70 to 75
32.8
29.8
0.0651
32.8
- 76 to 80
19.1
17.4
0.0424
19.1
- > than 80
16.9
16.9
0.2536
16.9
Gender (Male %)
62.0
40.6
0.4378
62.0
Race (%)
- Caucasian
85.4
81.2
0.1141
85.4
- Black
8.8
7.8
0.0369
8.8
- Others
5.8
11.0
0.0190
5.8
CCI
1.1 (1.5)
0.6 (1.2)
0.3654
1.1 (1.5)
Urban /Rural (%)
- Big Metro
50.4
51.7
0.0246
50.4
- Metro
31.0
31.0
0.0005
31.0
- Urban
6.3
6.2
0.0190
6.7
- Less urban
9.0
9.0
0.0255
9.7
- Rural
2.1
2.1
0.0002
2.1
Registry (%)
- S. Francisco
3.6
3.9
0.0143
3.6
- Connecticut
4.3
5.3
0.0430
4.3
- Detroit
5.7
5.5
0.0123
5.7
- Hawaii
1.2
1.3
0.0124
1.2
- Iowa
6.0
5.6
0.0135
6.0
- N Mexico
2.9
2.9
0.0013
2.9
- Seattle
5.2
5.5
0.0125
5.2
- Utah
2.2
2.1
0.0053
2.2
- Atlanta
2.0
3.0
0.0658
2.0
- San Jose
3.0
2.7
0.0152
3.0
- Los Angeles
5.9
7.6
0.0717
5.9
- Greater Cali
18.8
20.0
0.0306
18.8
- Kentucky
8.7
6.7
0.0751
8.7
- Louisiana
7.8
5.6
0.0880
7.8
- New Jersey
14.3
13.7
0.0182
14.3
- Georgia
8.5
8.6
0.0036
8.5
NOTE: Values in bold indicate reduction in standardized differences

74.2 (7.1)

Standardized
differences
after (1:1)
matching
0.0530

30.7
34.4
16.1
18.8
62.0

0.0121
0.0333
0.0768
0.0499
0.0608

84.5
10.1
5.4
1.2 (1.6)

0.0267
0.0461
0.0171
0.0233

50.8
31.0
6.6
9.2
2.4

0.0067
0.0012
0.0023
0.0173
0.0188

3.8
4.3
5.8
1.1
5.2
2.8
4.8
2.1
1.6
3.1
5.9
19.1
9.3
7.6
16.30
7.0

0.0119
0.0000
0.0024
0.0107
0.0318
0.0034
0.0206
0.0038
0.0253
0.0065
0.0023
0.0086
0.0215
0.0063
0.0546
0.0547
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Appendix 2.3 Characteristics of Renal Cell Carcinoma and non-cancer patients before and
after propensity score matching – continuing phase
Characteristic

RCC
(N =
10,408)

Age at diagnosis
Age categories
- 65 to 69
- 70 to 75
- 76 to 80
- > than 80
Gender (male
%)
Race (%)
- Caucasian
- Black
- Others
CCI
Urban /Rural (%)
- Big Metro
- Metro
- Urban
- Less urban
- Rural
Registry (%)
- S. Francisco
- Connecticut
- Detroit
- Hawaii
- Iowa
- N Mexico
- Seattle
- Utah
- Atlanta
- San Jose
- Los Angeles
- Greater Cali
- Kentucky
- Louisiana
- New Jersey
- Georgia

Standardize
d differences
before
matching
0.2573

RCC
(matched)
(N = 7,794)

Non-cancer
(matched)
(N = 7,794)

73.4 (6.1)

Noncancer
(N =
170,061)
75.1 (7.0)

Standardized
differences after
(1:1) matching

73.4 (6.1)

74.8 (7.0)

32.2
34.4
18.9
14.5
55.0

26.2
31.7
19.6
22.6
38.5

0.1316
0.0584
0.0168
0.2083
0.4379

32.2
34.4
18.9
14.5
55.0

30.7
34.4
19.6
21.5
58.9

0.0927
0.0714
0.0166
0.1814
0.0608

86.5
7.6
5.9
0.8 (1.3)

83.0
7.0
10.0
0.5 (0.9)

0.1142
0.0368
0.1904
0.3475

86.5
7.6
5.9
0.8 (1.2)

83.5
10.0
6.5
0.9 (1.3)

0.0267
0.0461
0.0171
0.0820

0.2128

51.4
30.3
6.4
9.4
2.4

51.7
30.4
6.4
9.3
2.2

0.0246
0.0005
0.0190
0.0254
0.0002

51.4
30.3
6.4
9.4
2.4

45.7
32.1
8.2
11.7
2.3

0.0067
0.0012
0.0022
0.0172
0.0188

3.0
6.1
5.6
1.2
6.3
2.6
5.4
1.7
2.7
2.3
6.3
18.2
8.1
7.6
14.2
8.7

3.8
5.7
5.4
1.3
5.7
2.8
5.4
2.2
2.7
2.6
7.4
19.5
6.7
5.8
14.4
8.4

0.0143
0.0430
0.0122
0.0123
0.0135
0.0013
0.0124
0.0052
0.0658
0.0152
0.0717
0.0305
0.0751
0.0879
0.0181
0.0035

3.0
6.1
5.6
1.2
6.3
2.6
5.4
1.7
2.7
2.3
6.3
18.2
8.1
7.6
14.2
8.7

1.5
6.2
5.6
1.8
6.5
4.3
4.3
1.5
1.1
3.7
6.0
18.5
6.4
11.4
14.0
7.4

0.0118
0.0000
0.0024
0.0106
0.0318
0.0034
0.0206
0.0038
0.0253
0.0065
0.0024
0.0086
0.0216
0.0063
0.0546
0.0546

NOTE: Values in bold indicate reduction in standardized differences
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Appendix 2.4 Characteristics of Renal Cell Carcinoma and non-cancer patients before and
after propensity score matching – late phase
Characteristic

Age at diagnosis
Age categories
- 65 to 69 (%)
- 70 to 75 (%)
- 76 to 80 (%)
- > than 80 (%)
Gender (male %)
Race (%)
- Caucasian
- Black
- Others
CCI
Urban /Rural (%)
- Big Metro
- Metro
- Urban
- Less urban
- Rural
Registry (%)
- S. Francisco
- Connecticut
- Detroit
- Hawaii
- Iowa
- N Mexico
- Seattle
- Utah
- Atlanta
- San Jose
- Los Angeles
- Greater Cali
- Kentucky
- Louisiana
- New Jersey
- Georgia

RCC
(N = 10,408)

Non-cancer
(N = 170,061)

76.9 (7.4)

81.6 (7.9)

19.1
26.5
22.6
31.8
57.0

7.9
16.0
19.2
56.9
38.8

88.3
7.7
4.0
1.4 (1.7)

Standardized
differences
before
matching
0.6184

76.9 (7.4)

Noncancer
(matched)
(N = 821)
76.9 (7.4)

0.3308
0.2582
0.0840
0.5208
0.3712

32.2
34.4
18.9
14.5
56.9

30.7
34.4
19.6
21.5
57.3

0.0216
0.0137
0.0176
0.0157
0.0607

84.7
7.1
8.2
1.1 (1.5)

0.1064
0.0224
0.1765
0.1933

88.3
7.7
4.0
1.4 (1.7)

91.0
6.6
2.4
1.3 (1.7)

0.0880
0.0426
0.0897
0.0377

47.1
29.3
7.5
13.2
2.8

49.9
31.4
6.8
9.8
2.2

0.0546
0.0458
0.0301
0.1086
0.0382

47.1
29.2
7.6
13.3
2.8

48.2
28.4
8.2
11.7
3.5

0.0219
0.0188
0.0226
0.0479
0.0417

2.6
3.8
4.5
1.1
8.3
2.6
4.9
2.8
2.9
1.3
8.0
20.1
9.0
7.8
11.9
8.3

3.3
5.6
7.1
1.1
6.2
2.8
5.1
2.2
2.8
2.1
6.8
18.4
7.2
6.4
14.2
8.8

0.0427
0.0858
0.1104
0.0031
0.0779
0.0151
0.0098
0.0363
0.0056
0.0561
0.0482
0.0523
0.0644
0.0523
0.0679
0.0180

2.6
3.8
4.5
1.1
8.3
2.6
4.9
2.8
2.9
1.3
8.0
20.3
9.0
7.8
11.9
8.3

1.7
3.5
6.6
1.5
6.5
1.7
5.1
4.0
2.9
1.3
6.2
19.5
10.7
8.2
13.3
7.3

0.0590
0.0129
0.0906
0.0325
0.0699
0.0590
0.0112
0.0671
0.0000
0.0000
0.0666
0.0214
0.0572
0.0134
0.0403
0.0363

NOTE: Values in bold indicate reduction in standardized differences
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RCC
(matched)
(N = 821)

Standardize
d differences
after (1:1)
matching
0.0048

Appendix 2.5 Distribution of propensity scores before and after matching by phases
A. Initial Phase
Before Match:

After Match:
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B. Continuing Phase
Before Match:

After Match:
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C. Late Phase
Before Match

After Match
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Appendix 2.6. Medical Consumer Price Index values for 2013 and 2015
Cost category
Hospital and ED
Outpatient
Carrier
SNF
Prescription
drugs
DME

Home health
Hospice care

Category used from
CPI report
Inpatient hospital
Outpatient hospital
Professional services
Nursing home and
adult day services
Prescription drugs

CPI in 2013

CPI in 2015

259.724
601.670
349.468
194.472

303.260
672.374
371.546
213.676

Multiplication
factor
1.168
1.118
1.063
1.099

442.580

502.510

1.135

Durable medical
equipment (medical
supplies and
equipment)
Home health
No specific category
(use medical care
which is average of
all services)

101.022

99.272

0.983

115.117
425.134

120.550
463.675

1.047
1.091

Source: Consumer Price Index for all Urban Consumers (CPI-U): U.S. city average, detailed expenditure
categories 2013 (January 2014 report) and 2015 (December 2015 report)
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Chapter 3
Study 2: Utilization of Targeted Therapy and Cytoreductive Nephrectomy among Older
Adults with Metastatic Renal Cell Carcinoma: Analysis of Survival and Healthcare Costs

ABSTRACT
Objectives
Since 2005, targeted therapies have become a standard of care for metastatic renal cell
carcinoma (mRCC). However, previous studies suggest that 25%-40% of mRCC patients do not
receive targeted therapies. Furthermore, due to availability of several targeted therapies, there is
uncertainty about the role of cytoreductive nephrectomy (CN) in the treatment of mRCC. The
specific aims of this study were 1) to examine the prevalence and predictors of targeted therapy
and CN use among older mRCC patients 2) to compare the survival and 3) to compare healthcare
costs among older patients who received targeted therapy alone versus CN + targeted therapy.
Methods
This study analyzed the 2007-2014 Surveillance Epidemiology and End Result (SEER)Medicare database. Patients newly diagnosed with primary mRCC at the age of 65 or more, who
also had continuous enrollment in Medicare Parts A, B and Prescription Drug Plans (PartD) were
included. First, we assessed the predictors of receiving either CN or targeted therapy (any active
treatment). A multivariable logistic regression assessed the odds for receiving active treatment
versus no active treatment. Second, we assessed predictors of receiving a CN + targeted therapy.
A multinomial logistic regression assessed the odds for receiving CN + targeted therapy and CN
alone versus targeted therapy alone. Third, we compared overall survival (OS), disease-specific
survival (DSS) and total healthcare costs (THC) between targeted therapy alone and CN + targeted
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therapy groups. A propensity score based inverse probability of treatment weighting (IPTW)
method was used to balance the two treatment groups. A Cox proportional hazard model assessed
the risk for death and a generalized linear model compared the healthcare costs between the groups.
All costs were inflated to 2016 U.S Dollars.
Results
Of 1,263 mRCC patients 672 (53%) received active treatment. Patients diagnosed at age >
80 years, with NCI comorbidity index scores ≥ 3, and with unknown tumor grade and metastases
to liver or brain were less likely to receive active treatment. Patients who were married, diagnosed
from 2010-2013 and with higher tumor involvement were more likely to receive active treatment.
Of patients receiving active treatment, 360 (54%) received targeted therapy alone, 201 (30%)
received CN + targeted therapy, and 111 (17%) received CN alone. Patients who had higher lymph
node involvement, metastasis to bone or liver, lived in North Central or West regions were
significantly less likely to receive CN + targeted therapy compared to targeted therapy alone.
Living in urban areas, higher tumor involvement, and poorly differentiated tumor grade increased
the odds for receiving CN + targeted therapy compared to targeted therapy alone. The median OS
from the adjusted survival curves was significantly higher (p <0.0001) for CN + targeted therapy
group (15 months) than the targeted therapy alone group (10 months). CN + targeted therapy group
had 0.63 times the risk of death (HR = 0.63) compared to the targeted therapy alone group. The
adjusted total healthcare cost per month was $17,159 for CN + targeted therapy group and $18,120
for the targeted therapy alone group (p = 0.4389). Sensitivity analysis suggested that total
healthcare cost tended to be higher for the targeted therapy alone group.
Conclusions
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About one-half of older mRCC patients on Medicare did not receive either CN or targeted
therapy. One-third of patients receiving targeted therapy also underwent CN. Use of CN among
targeted therapy users was associated with a higher median overall survival and disease-specific
survival and similar monthly total healthcare cost over a lifetime. Among clinically appropriate
mRCC patients, CN could play an important role in the targeted therapy era.
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BACKGROUND
Renal cell carcinoma (RCC) is the most common type of kidney cancer. About 9 out of 10
kidney cancers are RCC. The American Cancer Society (ACS) estimated that in 2017,
approximately 63,990 new kidney cancer cases would be diagnosed and 14,440 people would die
from this disease.1 The median age of RCC diagnosis is 64 years and men are at two times higher
risk than women to be diagnosed with RCC. About 15%-40% of RCC patients are diagnosed at
the metastatic stage and over 30% of those diagnosed at early stages eventually progress to the
metastatic stage.2, 3
Before 2005 (cytokine era), systemic therapies for mRCC included cytokine therapy with
high dose interleukin-2 and interferon-alpha. However, both drugs were associated with low tumor
response rate, high toxicity, and improvement of less than 6 to12 months in overall survival (OS).4,
5

Since 2005, the US Food and Drug Administration (FDA) approved several targeted therapies to

treat mRCC. These have demonstrated a significant improvement in survival outcomes compared
to cytokine therapies.6-10 These therapies included the tyrosine kinase inhibitors (TKI) sorafenib,
sunitinib, pazopanib, axitinib, and cabozantinib; the mammalian target of rapamycin inhibitors
(mTORi) everolimus and temsirolimus; the anti-vascular endothelial growth factor (VEGF)
monoclonal antibody bevacizumab and programmed death (PD)-1 check-point inhibitor,
nivolumab.
Currently, cytoreductive nephrectomy (CN) is considered standard prior to systemic
therapy in appropriate patients with mRCC. The combined use of CN and cytokine therapy
(referred as CN + targeted therapy henceforth) was well established in the cytokine era.
Prospective studies conducted during the cytokine era found that mRCC patients who underwent
CN followed by cytokine therapy had 6 months of higher median survival compared to patients
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that received cytokine therapy alone. 11-13 However, some studies reported that with the approval
of targeted therapies since 2005, utilization of CN among mRCC patients has decreased.14, 15 This
could be due to lack of randomized controlled trials demonstrating the efficacy of the CN +
targeted therapy. However, retrospective studies published in the last 4-5 years suggested that CN
+ targeted therapy resulted in a significantly higher OS compared to patients on targeted therapy
alone.16-18 Nevertheless, the appropriate sequence of therapy remains to be determined.
Several studies have been conducted among patients who initiated targeted therapies.
However, little is known about the prevalence and predictors of targeted therapy used alone or in
combination with CN among older patients that have reached the metastatic stage at the time of
incident RCC diagnosis. Previous studies conducted among younger populations suggested that
about 25-40% of mRCC patients did not receive targeted therapy.19, 20 This percentage could be
much higher among older adults due to the presence of comorbid conditions and frailty. These
factors could also affect survival outcomes among older patients. Further, none of the studies
compared healthcare cost between patients receiving targeted therapy alone versus CN + targeted
therapy. Medicare is the single largest payer for RCC patients, covering about 46% of all RCC
patients.1, 21 Targeted therapies cost from US $6,000 to $15,000 per month.22 In addition, CN and
post-surgical care may increase the overall healthcare cost among patients that received CN +
targeted therapy. However, patients undergoing CN may incur lower healthcare cost due to having
a several month gaps in targeted therapy treatment after surgery.
The first aim of this study was to examine the prevalence and predictors of targeted therapy
and CN use among older adults with mRCC. The study also described characteristics of patients
that used CN alone, targeted therapy alone and patients that did not receive either CN or targeted
therapy (referred to as any active treatment henceforth). The second aim of the study was to
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compare OS and disease-specific survival (DSS) among patients that received targeted therapy
alone versus CN + targeted therapy. The study hypothesized that patients that used CN + targeted
therapy compared to targeted therapy alone would have longer OS and DSS. The third aim of the
study was to compare healthcare cost between patients that received targeted therapy alone versus
CN + targeted therapy. We hypothesized that patients that received CN + targeted therapy would
incur higher healthcare cost than targeted therapy alone.
METHODS
Data Source23
SEER-Medicare
The Surveillance Epidemiology and End Result (SEER) program, initiated by the National
Cancer Institute (NCI), collects information on cancer statistics in an effort to reduce the cancer
burden among the U.S population.23 The information collected by this population-based cancer
registry includes demographics, incident cancer diagnosis, cause of death, cancer stage, tumor
characteristics, and surgery and radiation therapy provided during the first course of treatment. As
of 2017, SEER registries covered 28% of the U.S population.24 Medicare data provides
information on hospital (Part A), outpatient (Part B) and prescription drug (Part D) claims for
Medicare beneficiaries. SEER-Medicare links SEER and Medicare data and is an excellent source
to conduct population-based health services research on cancer patients in the U.S.
We used 2007-2014 SEER-Medicare data. The Patient Entitlement and Diagnosis
Summary File was used to obtain demographics and cancer diagnosis-related information.
Resource use and cost-related information were obtained from Medicare Provider Analysis and
Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies (HHA),
hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used to obtain
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inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on hospice
care utilization. The carrier file provided information on non-institutional physician-provided
services whereas the outpatient file provided information on institutional physician-provided
services. The PDE file provided data related to prescription medication use (Medicare Part D).
DME files provided data on the use of durable medical equipment while HHA files were used to
get information on services provided in patients’ homes.
Study Design and Sample Selection
This was a retrospective cohort study. The study first identified patients with diagnosis of
RCC using the International Classification of Diseases for Oncology, 3rd edition code C649 and
relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318'). The criteria developed by the
American Joint Committee on Cancer (AJCC) - 6th edition, was used to identify Stage-IV patients.
Further, we limited our sample to stage-IV patients with confirmed distant metastasis (M1 status).
We excluded patients aged < 65 years, diagnosed with another cancer at the time of RCC diagnosis,
diagnosed on autopsy, with cancer reported by death certificate, or enrolled in health maintenance
organization (HMO) plans. Figure 1 depicts the sample selection process in detail. Baseline
characteristics were identified from the year prior to mRCC diagnosis.
For OS we followed patients from diagnosis until death or until the end of December 2015.
For DSS, the study period ended on December 31, 2014 because information on RCC-specific
death was only available until the end of 2014. For cost comparisons, we assessed lifetime cost
defined as costs incurred from the first use of CN or targeted therapy (index date) until death.
Approximately 86% of the sample had a complete follow-up. We excluded patients that did not
have a complete follow-up from the cost analysis.
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Figure 3.1 Sample selection process for this study.
SEER-Medicare population diagnosed
with Kidney and Renal Pelvis cancer
from January 2007 to December 2013
(n = 57,660)
Kidney cancers other than RCC
and patients with multiple cancers
(n =22,476)
Registry confirmed first primary RCC
diagnosis using ICD-O codes C.64.9
(n = 35,184)
•
•
•
•

RCC patients diagnosed at age ≥ 65
years with continuous Medicare Parts
A, B and D enrollment
(n = 6,581)

Patients aged < 65 years (n = 12,444)
Diagnosed on autopsy (n = 171)
Missing date of diagnosis (n = 136)
Not continuously enrolled in
Medicare Parts A and B (n = 2,626)
• Had HMO coverage (n = 7,227)
• Not continuously enrolled in Part D
prescription drug plan (n = 5,999)

•

Patients with earlier and unknown
stages (n = 5,243)
Distant metastasis absent (n = 75)

•

Stage-IV RCC cohort
(n =1,263)
•
Patients with CN alone
(n = 111) or no active
treatment (n = 591)

•
•
Survival analysis
(n =561)

Cost analysis
(n =474)
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Patients with CN alone (n = 111)
or no active treatment (n = 591)
Incomplete follow-up (n < 90)
Outliers (n =<11)

Study Measures
The study first compared predictors of any active treatment (CN or targeted therapy) versus
no active treatment. Then, among patients that received active treatment, we assessed predictors
of CN alone and CN + targeted therapy compared to targeted therapy alone as a reference group.
Comparisons for survival and costs were conducted between targeted therapy alone and CN +
targeted therapy groups. Patients that received CN alone or did not receive active treatment were
excluded from the survival and cost comparisons.
Targeted therapy / Cytoreductive Nephrectomy
Oral targeted therapies were identified using generic names and National Drug Codes
(NDCs) from Medicare Part D while injectable-targeted therapies were identified using healthcare
procedural codes (HCPC) from Medicare Part B data. Information related to partial or radical
nephrectomy was obtained from a combination of SEER registry codes, the Current Procedural
Terminology (CPT) codes from outpatient and carrier files, and ICD9- CM procedure codes from
inpatient hospital files. The date of first targeted therapy or CN use after mRCC diagnosis was
considered as the index date. The codes used to identify targeted therapies and CN can be found
in the Appendix.
Overall survival /disease-specific survival
The study defined overall survival as the time in months from the date of diagnosis until
the date of death or until the end of 2015. Both OS and DSS were calculated. Cause of death
information from registry data (PEDSF file) was used to identify RCC specific death to calculate
DSS. Patients that were alive beyond the end of December 2014 were censored.
Healthcare costs
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Costs were the amounts reimbursed by Medicare for each claim related to health services
utilized by mRCC patients from index date until death. Costs were reported as monthly costs. Total
healthcare cost was further categorized into prescription drug cost and medical cost.
Other variables
These variables included patient’s sociodemographics, tumor characteristics, site of
metastasis, histology, claims-based performance status and NCI comorbidity index score.
Information on these variables was obtained in the year prior to mRCC diagnosis.
Statistical Analysis
The study first compared characteristics across treatment modalities using Chi-square test
for categorical variables and ANOVA for continuous variables. Multivariable (binary) logistic
regression assessed predictors of active treatment. Among patients who received active treatment,
multinomial logistic regression was used to assess predictors of CN + targeted therapy and CN
alone compared to targeted therapy alone. The Andersen Behavior Model (ABM) was used to
guide the selection of variables (see Figure 2). As per the ABM, factors associated with choice of
treatment can be characterized into ‘predisposing’ (e.g. age, sex, race), ‘enabling’ (e.g., education
and income measured at the zip code level), and ‘need’ (e.g. tumor characteristics, histology, NCI
comorbidity score) factors.25, 26
A Kaplan Meier curve and log-rank test compared the unadjusted median OS and DSS for
targeted therapy alone versus CN + targeted therapy groups. To reduce selection bias, we
calculated propensity score-based inverse probability of treatment weights (IPTW). In the first
step, we calculated the propensity (probability) of a patient receiving CN + targeted therapy versus
targeted therapy alone. In the second step, individuals were weighted by the inverse probability of
receiving the treatment that they actually received. To reduce the bias resulting from extreme
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weights or propensity scores, stabilized weights were calculated using a technique described by
Robins et al (2000) and Austin et al. (2009).27, 28 Stabilized weights were then used in a Cox
proportional hazard model to calculate the risk of death between the two groups. Survival
probabilities from the Cox proportional hazard model were used to describe adjusted survival
curves and median survival for both the groups.
Similar to survival outcomes, costs were compared using stabilized IPTWs. Due to the
skewed nature of cost data, generalized linear models (GLMs) with log link and gamma
distribution was chosen based on results from Modified Park tests, Pearson correlation tests,
Pregibon link tests, and modified Hosmer and Lemeshow tests. All costs were inflated to 2016
USD using the Consumer Price Index for medical care services and medical care commodities.29
All statistical analyses were conducted at an alpha level of 0.05 using SAS v.9.4 (SAS Institute
Inc., Cary, NC), and STATA (version 13.0, StataCorp, College Station, TX).
Additional Analyses
Some mRCC patients may receive delayed treatment or may not require immediate
treatment with CN or targeted therapy after being diagnosed with mRCC. This may affect the
comparison of OS and DSS in the study because survival was measured from the date of diagnosis
and not from the date of treatment initiation. To understand the effect of the definition of the
follow-up period, we measured survival as the time from treatment initiation until death or until
the end of the study period. In addition, we used multivariable regression methods instead of
propensity score-based IPTW to compare survival outcomes and healthcare costs between patients
who received targeted therapy alone and CN + targeted therapy.
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Figure 3.2 Conceptual framework adapted from the Anderson Behavioral Model to predict
the choice of treatment.
Predisposing factors
age, sex, race, marital
status
Enabling factors
Zip code level income
and education, urban rural status

Treatment choice
(Targeted therapy alone, CN alone,
CN + targeted therapy, none)

Need factors
Tumor grade, site of
metastasis, histology,
NCI comorbidity score,
performance status
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RESULTS
Prevalence of Treatment Modalities
The final study sample included 1,263 patients. Of these, 360 (29%) patients received
targeted therapy alone, 201 (16%) received CN+ targeted therapy, 111 (9%) patients received CN
alone and 591 (47%) patients did not receive CN or targeted therapy. Characteristics of patients
across treatment modalities are presented in Table 3.1

Predictors of receiving CN or targeted therapy versus none
Multivariable binary logistic regression analysis found that patients who were aged > 80
years at the time of diagnosis, had NCI comorbidity score of 3 or more, had unknown tumor grade,
had liver or brain metastasis, and used home health service before diagnosis were significantly (p
<0.05) less likely to receive CN or targeted therapy. Patients who were married, were diagnosed
between 2010-2013, and had higher tumor involvement and a higher number of ED visits before
diagnosis were significantly (p <0.05) more likely to receive CN or targeted therapy. Gender, race,
SEER region, urban/rural status, tumor size, the extent of lymph node involvement, lung or bone
metastasis, baseline physician visits or DME use were not significant predictors of receiving CN
or/targeted therapy (Table 3.2).
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Table 3.1 Characteristics of mRCC patients by treatment group in study 2
Characteristic

Age at diagnosis (years) +
- 65-69
- 70-75
- 76-80
- More than 80
Sex +
- Male
- Female
Race/Ethnicity +
- White
- Black /others
Marital status +
- Married
- Single/Divorced/Separated
Zip code- college educated +
- 0 to 15%
- 16-20%
- 21-30%
- 31% and above
Zip code level median household
income (USD) +
- < 40k
- 40k - 50 k
- 51k - 70k
- > 70 k
Urban/Rural Status
- Big Metro
- Metro /Urban
- Less urban / Rural
SEER region
- Northeast
- South
- North Central
- West
Year of diagnosis +
- 2007 to 2009
- 2010 to 2013
NCI comorbidity index score +
-0
-1
-2
- 3 or more

Targeted
therapy alone
(n = 360)
n, %

CN alone
(n = 111)
n, %

CN + targeted
therapy
(n= 201)
n, %

93 (26)
121 (34)
89 (25)
57 (16)

30 (27)
34 (31)
34 (31)
13 (12)

77 (38)
69 (34)
44 (22)
11 (6)

93 (16)
122 (21)
130 (22)
246 (42)

209 (58)
151 (42)

60 (54)
51 (46)

127 (63)
74 (37)

294 (50)
297 (50)

304 (84)
56 (16)

>95 (>89)
<11 (<10)

178 (89)
23 (11)

500 (85)
91 (15)

186 (52)
174 (48)

65 (59)
46 (41)

130 (65)
71 (35)

229 (39)
362 (61)

105 (29)
66 (18)
75 (21)
114 (32)

30 (27)
23 (21)
27 (24)
31 (28)

42 (21)
28 (14)
46 (23)
85 (42)

189 (32)
100 (17)
131 (22)
171 (29)

90 (25)
85 (24)
98 (27)
87 (24)

20 (18)
30 (27)
35 (32)
26 (23)

34 (17)
38 (19)
65 (32)
64 (32)

157 (26)
147 (25)
160 (27)
127 (22)

62 (17)
158 (44)
140 (39)

18 (16)
51 (46)
42 (38)

19 (10)
104 (52)
78 (39)

87 (15)
282 (48)
222 (38)

55 (15)
94 (26)
47 (13)
164 (46)

24 (22)
28 (25)
16 (14)
43 (39)

38 (19)
60 (30)
20 (10)
83 (41)

101 (17)
167 (28)
85 (14)
238 (40)

125 (35)
235 (65)

47 (42)
64 (58)

64 (40)
100 (60)

272 (46)
319 (54)

136 (38)
106 (29)
43 (12)
75 (21)

55 (50)
26 (23)
18 (16)
12 (11)

89 (45)
67 (33)
22 (11)
23 (11)

196 (33)
138 (23)
86 (15)
171 (29)

+ Statistically significant differences based on chi-square test / ANOVA, p < 0.05
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None
(n = 591)
n, %

Table 3.1 Continued
Characteristic

NCI comorbidity index score +
(mean, standard deviation)

Targeted
therapy alone
(n = 360)
n, %

CN alone
(n = 111)
n, %

CN + targeted
therapy
(n = 201)
n, %

None
(n = 591)
n, %

1.3 (1.5)

0.9 (1.2)

1.0 (1.2)

1.8 (2.0)

66 (23)
88 (31)
134 (47)

21 (19)
34 (30)
55 (50)

22 (12)
56 (29)
114 (59)

129 (29)
149 (33)
173 (38)

42 (11)
25 (7)
293 (82)

23 (21)
66 (60)
22 (20)

44 (21)
111 (59)
46 (20)

21 (4)
42 (7)
528 (89)

186 (52)
59 (16)
79 (22)
36 (10)

23 (21)
14 (13)
61 (55)
13 (12)

31 (15)
32 (16)
122 (61)
16 (8)

363 (61)
78 (13)
97 (16)
53 (9)

250 (69)
110 (31)

88 (79)
23 (21)

153 (76)
48 (24)

458 (77)
133 (23)

333 (93)
27 (7)

94 (85)
17 (15)

174 (87)
27 (13)

547 (93)
44 (7)

177 (49)
204 (57)
74 (21)
51 (14)

26 (23)
54 (49)
22 (16)
13 (12)

57 (28)
113 (56)
18 (10)
17 (9)

253 (43)
319 (54)
145 (25)
96 (16)

4.0 (3.3)
0.5 (1.8)
1.0 (8.5)
31.0 (24.9)
0.2 (0.7)

4.0 (3.7)
1.7 (9.2)
2.5 (16.5)
29.9 (25.4)
0.1 (0.5)

4.2 (3.7)
0.7 (2.4)
0 (0)
30.4 (25.3)
0.0 (0.3)

2.9 (2.7)
1.6 (6.4)
4.2 (17.0)
36.2 (35.3)
0.4 (1.0)

140 (39)
76 (21)

39 (35)
14 (13)

59 (29)
20 (10)

249 (42)
130 (22)

+

Tumor size
- Unknown / < 5 cm
- 5 to 7.9 cm
- ≥ 8 cm
Tumor grade +
- Well/ moderate
- Poor / undifferentiated
- Unknown
Tumor extent (T) - TNM +
- T0 / T1/ unknown
- T2
- T3
- T4
Lymph Node (N) - TNM +
- N0 /NX
- N1 /N2
Histology
- Clear cell
- Non-clear cell
Site of metastasis
- Bone (yes)
- Lung (yes)
- Liver (yes)
- Brain (yes)
Performance status indicators
Average number of services
(mean, standard deviation)
- ED visits +
- hospital days+
- SNF days+
- physician claims +
- home health claims+
DME use (%) +
Assisting devices (%) +

+ Statistically significant differences based on chi-square test / ANOVA, p < 0.05
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N),
and the presence of metastasis (M).
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Table 3.2 Multivariable logistic regression assessing predictors of CN or targeted therapy
(any treatment) versus no treatment among mRCC patients.
Characteristic

Odds Ratio
(CN/ targeted therapy vs None)

Age at diagnosis (years)
- 65-69
- 70-75
- 76-80
- More than 80
Sex
- Female
- Male
Race/Ethnicity
- Black /others
- White
Marital status
- Single/Divorced/Separated
- Married
Zip code- college educated
- 0 to 15%
- 16-20%
- 21-30%
- 31% and above
Zip code level median household
income (USD)
- < 40k
- 40k - 50 k
- 51k - 70k
- > 70 k
Urban/Rural Status
- Less urban / Rural
- Metro /Urban
- Big Metro
SEER region
- Northeast
- South
- North Central
- West
Year of diagnosis +
- 2007 to 2009
- 2010 to 2013
NCI comorbidity index score +
-0
-1
-2
- 3 or more

95% CI

p-value

Reference
0.98
0.78
0.25

0.66 - 1.46
0.52 - 1.18
0.16 - 0.38

<0.0001

Reference
1.04

0.77 - 1.41

Reference
0.96

0.64 - 1.43

0.8211

Reference
1.80

1.33 - 2.42

0.0001

Reference
1.61
1.57
1.48

1.02 - 2.51
0.99 - 2.47
0.88 - 2.49

0.0390
0.0532
0.1385

Reference
0.78
0.88
1.01

0.50 - 1.21
0.55 - 1.41
0.56 - 1.84

0.2611
0.5938
0.9645

Reference
0.81
0.80

0.49 - 1.33
0.50 - 1.27

0.3974
0.3377

Reference
1.00
0.74
1.00

0.62 - 1.64
0.43 - 1.29
0.67 - 1.51

0.9720
0.2852
0.9728

Reference
1.66

1.24 - 2.24

0.0008

Reference
1.11
1.30
0.55

0.77 - 1.61
0.50 - 1.24
0.34 - 0.88

0.5666
0.2971
0.0124

Note: p-value < 0.05 indicates statistically significant association
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0.8079

Table 3.2 (continued)
Characteristic

Odds Ratio
(CN / targeted therapy
vs None)

95% CI

p-value

Tumor size
- Unknown / < 5 cm
- 5 to 7.9 cm
- ≥ 8 cm

Reference
1.12
1.30

0.77 - 1.61
0.86 - 1.96

0.5619
0.2078

Tumor grade
- Well/ moderate
- Poor / undifferentiated
- Unknown

Reference
0.66
0.15

0.34 - 1.28
0.08 - 0.26

0.2134
<0.0001

Reference
1.37
2.30
1.56

0.84 - 2.21
1.55 - 3.40
0.93 - 2.62

0.2043
<0.0001
0.0928

Reference
0.95

0.68 - 1.31

0.7464

Reference
1.06

0.64 - 1.73

0.8288

Reference
1.00

0.75 - 1.36

0.9641

Reference
0.76

0.57 - 1.02

0.0673

Reference
0.59

0.42 - 0.83

0.0023

Reference
0.48

0.32 - 0.72

0.0004

1.24
0.97
0.99
1.00
0.75
0.96
1.10

1.17 - 1.31
0.94 - 0.99
0.98 - 1.00
0.99 - 1.01
0.60 - 0.93
0.65 - 1.42
0.70 - 1.73

<0.0001
0.0273
0.2474
0.1889
0.0102
0.8436
0.6881

Tumor extent (T) - TNM +
- T0 / T1/ unknown
- T2
- T3
- T4
Lymph Node (N) - TNM
- N0 /NX
- N1 /N2
Histology
- Non-clear cell
- Clear cell
Bone metastasis
- Absent
- Present
Lung metastasis
- Absent
- Present
Liver metastasis
- Absent
- Present
Brain metastasis
- Absent
- Present
Performance status indicators
Average number of services
- ED visits
- hospital days
- SNF days
- physician claims
- home health claims
DME use (Yes vs No)
Assisting devices (Yes vs No)

Note: p-value < 0.05 indicates statistically significant association
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the
presence of metastasis (M).
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Predictors of receiving CN+ targeted therapy versus targeted therapy alone.
Multinomial logistic regression analysis found that patients who were > 80 years old at the
time of diagnosis, lived in North Central or West regions, had higher lymph node involvement,
had bone or liver metastasis, had unknown tumor grade were significantly (p <0.05) less likely to
receive CN + targeted therapy compared to targeted therapy alone. Patients who lived in urban
areas, had higher extent of tumor involvement, had poorly differentiated tumor grade, had a higher
number of ED visits before cancer diagnosis were significantly (p <0.05) more likely to receive
CN+ targeted therapy versus targeted therapy alone.
Predictors of receiving CN alone versus targeted therapy alone.
Multinomial logistic regression analysis found that patients who had NCI comorbidity
score of 3 or more, lived in South, North Central or West regions, had higher lymph node
involvement, had bone or lung metastasis, had unknown tumor grade were significantly (p <0.05)
less likely to receive CN alone compared to targeted therapy alone. Patients who had greater extent
of tumor involvement, poorly differentiated tumor grade, and more hospital stays before cancer
diagnosis were significantly (p <0.05) more likely to receive CN alone compared to targeted
therapy alone. (Table 3.2)
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Table 3.3 Multinomial logistic regression assessing predictors of CN + targeted therapy and
CN alone versus targeted therapy alone among older mRCC patients.
Characteristic

Age at diagnosis (years)
- 65-69
- 70-75
- 76-80
- More than 80
Sex
- Female
- Male
Race/Ethnicity
- Black /others
- White
Marital status
- Single/Divorced/Separated
- Married
Zip code- college educated
- 0 to 15%
- 16-20%
- 21-30%
- 31% and above
Zip code level median
household income (USD)
- < 40k
- 40k - 50 k
- 51k - 70k
- > 70 k
Urban/Rural Status
- Less urban / Rural
- Metro /Urban
- Big Metro
SEER region
- Northeast
- South
- North Central
- West
Year of diagnosis
- 2007 to 2009
- 2010 to 2013
NCI comorbidity index score
-0
-1
-2
- 3 or more

CN alone (N = 111)
vs targeted therapy alone
(N = 360)
Odds Ratio
95% CI

CN + targeted therapy (N = 201)
vs targeted therapy alone
(n = 360)
Odds Ratio
95% CI

Reference
0.94
1.24
0.74

0.45 - 1.96
0.57 - 2.68
0.27 - 2.02

Reference
0.73
0.60
0.24

0.40 - 1.35
0.31 - 1.17
0.09 - 0.61

Reference
0.92

0.49 - 1.74

Reference
1.26

0.72 - 2.21

Reference
1.89

0.74 - 4.80

Reference
1.39

0.64 - 3.04

Reference
1.12

0.59 - 2.11

Reference
1.31

0.76 - 2.27

Reference
0.81
1.06
0.48

0.33 - 1.98
0.43 - 2.65
0.16 - 1.42

Reference
0.95
1.53
1.53

0.41 - 2.17
0.67 - 3.49
0.60 - 3.87

Reference
1.51
1.81
1.49

0.59 - 3.85
0.66 - 4.92
0.41 - 5.47

Reference
0.88
1.13
0.71

0.39 - 2.02
0.47 - 2.70
0.24 - 2.12

Reference
1.41
0.99

0.53 - 3.76
0.40 - 2.41

Reference
3.62
1.94

1.45 - 9.06
0.84 - 4.48

Reference
0.37
0.19
0.24

0.14 - 0.98
0.06 - 0.61
0.10 - 0.54

Reference
0.98
0.30
0.41

0.43 - 2.24
0.10 - 0.86
0.21 - 0.84

Reference
1.31

0.70 - 2.42

Reference
1.29

0.75 - 2.21

Reference
0.54
1.10
0.20

0.26 - 1.14
0.45 - 2.70
0.07- 0.61

Reference
0.99
0.74
0.40

0.54 - 1.83
0.32 - 1.71
0.16 - 1.00

Notes: Values in bold indicate a statistically significant association
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Table 3.3 (continued)
Characteristic

CN alone (N = 111)
vs targeted therapy alone (N = 360)
Odds Ratio

Tumor size
- Unknown / < 5 cm
- 5 to 7.9 cm
- ≥ 8 cm
Tumor grade
- Well/ moderate
- Poor / undifferentiated
- Unknown
Tumor extent (T) - TNM
- T0 / T1/ unknown
- T2
- T3
- T4
Lymph Node (N) - TNM
- N0 /NX
- N1 /N2
Histology
- Non-clear cell
- Clear cell
Bone metastasis
- Absent
- Present
Lung metastasis
- Absent
- Present
Liver metastasis
- Absent
- Present
Brain metastasis
- Absent
- Present
Performance status indicators*
Average number of services
- ED visits
- hospital days
- physician claims
- home health claims
DME use (Yes vs No)
Assisting devices (Yes vs No)

95% CI

CN + targeted therapy (N = 201)
vs targeted therapy alone (360)
Odds Ratio

95% CI

Reference
1.42
1.28

0.62 - 3.19
0.54 - 3.02

Reference
1.35
1.42

0.66 - 2.76
0.67 - 2.99

Reference
6.36
0.16

2.71 - 14.88
0.07 - 0.35

Reference
4.63
0.16

2.15 - 9.98
0.08 - 0.30

Reference
2.13
5.56
2.48

0.78 - 5.81
2.46 - 12.57
0.82 - 7.55

Reference
2.13
6.17
1.72

0.92 - 4.91
3.06 - 12.43
0.61 - 4.82

Reference
0.17

0.08 - 0.36

Reference
0.26

0.14 - 0.49

Reference
2.58

0.98 - 6.74

Reference
2.21

0.93 - 5.27

Reference
0.30

0.16 - 0.56

Reference
0.45

0.26 - 0.78

Reference
0.49

0.27 - 0.90

Reference
0.77

0.46 - 1.31

Reference
0.93

0.45 - 1.95

Reference
0.48

0.24 - 0.95

Reference
0.97

0.39 - 2.42

Reference
0.52

0.23 - 1.21

1.08
1.14
1.00
1.37
1.27
0.72

0.98 - 1.17
1.01 - 1.28
0.98 - 1.01
0.85 - 2.20
0.57 - 2.84
0.26 - 1.97

1.10
1.07
1.00
0.43
0.84
0.70

1.02 - 1.19
0.95 - 1.20
0.99 - 1.02
0.17 - 1.10
0.41 - 1.72
0.28 - 1.77

Notes: Values in bold indicate statistically significant association; * SNF use was excluded due to small sample size
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the
presence of metastasis (M).
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Overall Survival and Disease-Specific Survival between CN + Targeted therapy versus
Targeted therapy Alone.
Unadjusted Kaplan Meier analysis found that the median OS for CN+ targeted therapy
group was significantly higher than for the targeted therapy alone group (21 months vs 10 months,
p <0.0001). Similarly, CN + targeted therapy group had significantly higher DSS than the targeted
therapy alone group (20 months vs 10 months, p <0.0001). Kaplan Meier curves for the OS and
DSS are displayed in Figure 3.2
A Cox proportional hazard model after IPTW found that compared to patients that received
targeted therapy alone, CN+ targeted therapy group had 0.59 times lower risk for death (HR =
0.59, 95% CI: 0.56 - 0.62; p <0.0001) due to any reason (OS). Similarly, CN + targeted therapy
group had 0.63 times lower risk for RCC-related death (DSS) (HR = 0.63, 95%CI: 0.60 - 0.67; p
<0.0001) compared to CN + targeted therapy group. Additionally, we used survival probabilities
from the Cox proportional model to describe adjusted survival curves for OS and DSS (Figure 3).
Adjusted survival curves indicated that the median OS and DSS were 5 months higher for CN+
targeted therapy group (15 months) compared to targeted therapy alone (10 months).
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Figure 3.3 Kaplan Meier Survival curves comparing overall survival and disease-specific
survival between CN+ targeted therapy and targeted therapy alone groups.
a. Overall survival

b. Disease specific survival

NOTE: Statistically significant difference for OS and DSS; p-value < .0001
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Figure 3.4 Adjusted overall survival and disease-specific survival between CN + targeted
therapy and targeted therapy alone groups.
a) Overall survival

b) Disease-specific survival

NOTE: Statistically significant difference for OS and DSS; p-value <0.0001
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Healthcare Cost between CN + Targeted therapy vs Targeted therapy Alone.
Unadjusted average (monthly) total healthcare cost, medical cost and prescription drug cost
are described in Table 3.4 There was no statistically significant difference in the total healthcare
cost and medical cost between CN + targeted therapy and targeted therapy alone groups. However,
prescription drug costs were significantly higher (p<0.05) for the targeted therapy alone group
($5,701) compared to CN + targeted therapy group ($2,692).
Generalized linear models using the log link and gamma distribution (after propensity score
based IPTW) indicated that the total healthcare cost was similar (p = 0.4389) for the targeted
therapy alone group ($ 18,120) compared to CN + targeted therapy group ($ 17,159). The medical
cost was significantly higher for CN + targeted therapy group ($ 14,197) compared to targeted
therapy alone group ($ 10,607); whereas prescription drug cost ($ 7,573) was significantly higher
for the targeted therapy alone group compared to CN + targeted therapy group ($ 2,962).

Table 3.4 Unadjusted comparison of total healthcare costs, medical costs and prescription
drug costs between CN+ targeted therapy and Targeted therapy alone groups.

Monthly Costs

CN + targeted therapy (n = 154)

Targeted therapy alone (n = 326)

Mean (US $)

Mean (US $)

Median (US $)

Median (US $)

Total healthcare costs

14,005

11,551

17,012

12,596

Medical costs

10,925

7,784

11,310

7,737

3,081

2,692

5,701

* 4,751

Prescription drug costs

* Significantly higher cost (p <0.05) based on Wilcoxon Mann Whitney test
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Table 3.5. Generalized linear model (including IPTWs) assessing total healthcare costs,
medical costs and prescription drug costs between CN+ targeted therapy and targeted
therapy alone groups.
Average costs per month

CN + targeted therapy
(n = 154)
Mean (95%CI)

Targeted therapy alone
(n = 326)
Mean (95%CI)

p-value

Total healthcare costs

17,159 (15,294 - 19,252)

18,120 (16,791 - 19,554)

0.4389

Medical costs

14,197 (12,385 - 16,275)

10,607 (9,689 - 11,612)

0.0005

2,962 (2,482 - 3,535)

7,573 (6,735 - 8,516)

<0.0001

Prescription drug costs

Note: Covariates were included in the propensity score model to calculate IPTWs. The generalized linear model was
run after IPTW to get cost estimates.

Additional Analysis
First, we assessed sociodemographic and clinical predictors of targeted therapy use among
mRCC patients. Details about the predictors of targeted therapy use are described in Appendix 3.7
Patients that were younger at the time of diagnosis, married, and diagnosed in the late targeted
therapy era had higher odds for receiving targeted therapies. As the NCI comorbidity score
increased the odds for patients receiving targeted therapy decreased. Further, presence of liver or
brain metastasis, and poor or unknown tumor grade decreased the odds for receiving targeted
therapies. Odds for receiving targeted therapies also decreased with an increase in the average
number of hospital stays and home health visits. Second, we assessed the overall survival between
mRCC patients who received targeted therapies and patients who did not. These results can be
found in Appendix 3.8. Adjusted survival curves suggested that median OS was 9 months for
targeted therapy users and 4 months for patients that did not receive targeted therapies. A Cox
proportional hazard model (after IPTW) found that patients who received targeted therapies had
0.57 times risk of death compared to patients who did not receive targeted therapy (HR = 0.57,
95%CI: 0.51 - 0.64, p < 0.0001).
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Third, for the survival analysis that compared CN + targeted therapy and targeted therapy
alone groups, we considered survival as the time from treatment initiation (either CN or targeted
therapy) to death or end of 2014. The adjusted OS and DSS curves and hazard ratios were similar
to our main analysis where survival was measured as a time from diagnosis. Fourth, instead of
propensity scoring, we used multivariable Cox proportional hazard models. In the model assessing
OS, patients from CN + targeted therapy had 0.37 (95% CI: 0.28 - 0.49) times lower risk of death
compared to targeted therapy alone controlling for all other covariates. The risk of death for CN +
targeted therapy was much lower in the regression model as compared to propensity score-based
method, which suggested that our findings based on propensity score-based IPTW method were
more conservative than the regression approach. Fifth, similar to survival outcomes, for the cost
analysis, we conducted multivariable regression analysis instead of propensity score-based IPTW.
Costs from the multivariable GLM indicated higher total healthcare cost for the targeted therapy
alone group, most of which, was driven by higher prescription drug costs as medical costs were
similar between the groups.

Discussion
This study analyzed SEER-Medicare data to compare survival and healthcare costs among
mRCC patients diagnosed at age 65 and older, who received CN and targeted therapy versus
targeted therapy alone. We also assessed the prevalence and predictors of targeted therapy and/or
CN use in this population. Among newly diagnosed mRCC patients, only 44% received targeted
therapy and 25% received CN. About 47% did not receive either targeted therapy or CN, which
are considered as primary treatments for mRCC. Patients who received CN and targeted therapy
had higher OS and DSS compared to patients who received targeted therapy alone. Average
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monthly total healthcare costs were similar for patients who received CN and targeted therapy
versus targeted therapy alone.
The prevalence of targeted therapy recipients in our study (44%) was much lower than an
estimate of 60-70% reported by studies conducted among younger populations.19, 20 Similarly, the
prevalence of any active treatment (53%) in our study was also much lower than the prevalence
(70%) reported in previous studies. However, it was higher than the estimate from a study
conducted among older Medicare patients in the cytokine era, in which only 30% patients received
either CN or cytokine therapy.30 Additionally, patients diagnosed in the later part of targeted
therapy era (2010-2013) were more likely to receive active treatment. This suggested that a higher
number of older mRCC patients received active treatment in the targeted therapy era, probably
because more targeted therapies became available. This trend was consistent with the findings
from Banegas et al.19 Patients aged ≥ 80 years at the time of diagnosis and who were single/
unmarried/ divorced were less likely to receive CN or targeted therapy. These findings were
consistent with previous studies.19, 30. However, in contrast to Saigal et al.30 we did not find any
racial/ethnic disparity in our study. Clinical factors - unknown tumor grade, NCI comorbidity
index score of ≥ 3, presence of liver/ brain metastasis, hospital stays and home health service use
in the year prior to diagnosis were associated with not receiving active treatment. This suggested
that patients who had higher comorbidities or poor health status at the time of diagnosis were not
good candidates to receive active treatment; possibly because the risks associated with active
treatment might outweigh their benefits.
Among patients that received active treatment, we assessed predictors of receiving CN +
targeted therapy compared to patients that received targeted therapy alone. Results from the
multivariable model indicated that patients with advanced age at the time of cancer diagnosis,
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comorbidities, metastases to liver/ bone/ brain, and higher lymph node involvement were less
likely to receive CN + targeted therapy compared to targeted therapy alone. Poor/undifferentiated
tumor grade or T3 stage was associated with higher odds to receive CN. These findings were
consistent with findings from Hanna et al.17 In addition, we observed a geographical discrepancy
in the use of CN such that patients from rural areas (compared to urban) or living in North Central
and West regions (compared to Northeast region) were less likely to receive CN with or without
targeted therapy. Future studies could further investigate reasons for geographical disparity for CN
use among mRCC patients.
Findings from the adjusted survival analysis suggested that the use of CN among targeted
therapy users was associated with six additional months of median OS. Unadjusted Kaplan Meier
analysis suggested an additional OS of 10 months. Results from a Cox proportional hazard model
after IPTW suggested that patients who used both CN and targeted therapy had a lower risk of
death compared to patients receiving targeted therapy alone. The results from the propensity score
based IPTW model were more conservative than the multivariable regression model but had the
same directionality. Our findings were consistent with the findings from previous retrospective
studies.16, 17 Heng et al. analyzed IMDC database and found that the risk of death for targeted
therapy users who received CN was significantly lower (HR = 0.60, 95% CI: 0.52 - 0.69) than
patients who received targeted therapy alone.16 Similarly, Hanna et al, using the National Cancer
Data Base (NCDB), found that patients who received both CN and targeted therapy had a lower
risk of death (HR = 0.49, 95%CI: 0.46 to 0.52) compared to patients on targeted therapy alone.17
Findings from our and other retrospective studies, however, were not consistent with a
recently published prospective RCT (CARMENA).31 This non-inferiority RCT compared survival
outcomes among patients receiving CN followed by sunitinib versus sunitinib alone. The study
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found that the sunitinib alone group had a higher OS (18.4 months) than patients who received CN
and sunitinib (13.9 months). The HR of 0.89 (95%CI: 0.71- 1.10) was non-significant suggesting
that sunitinib alone was not considered inferior to patients who received CN + sunitinib. No
significant differences were observed for other outcomes such as progression free survival. This is
the only prospective study that has assessed the role of CN among mRCC patients in the targeted
therapy era.
As prospective studies have better internal validity and minimal selection bias, they are often
considered as the gold standard and provide a higher level of evidence than retrospective studies.
As a result, use of CN among mRCC patients may be questioned in the near future. Conflicting
findings from the CARMENA study compared to retrospective studies may generate uncertainty
in decision-making, as the risk associated with CN may not outweigh survival benefits among
mRCC patients.
It is important to highlight key differences between CARMENA study and our study. The
CARMENA study included patients that were good candidates for CN and sunitinib and excluded
patients who had brain metastasis, cardiovascular comorbidities or poor performance status. The
median age was 62 years. In contrast, in our study, the median age was 73 years. We did not
exclude patients based on metastasis, comorbidities or performance status. Further, although the
CARMENA study was randomized there were differences between treatment groups for the extent
of tumor (T) and lymph node (N) involvement. These differences may affect survival outcomes
between the treatment groups. In our study, we controlled for these differences using the IPTW
method. CARMENA study controlled for prognostic risk calculated using MSKCC criteria.
Although our study did not control for prognostic risk, other retrospective studies whose findings
were similar to ours did control for baseline risk of prognosis.
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As a prospective RCT, the CARMENA study certainly had higher internal validity than
retrospective studies but the stricter inclusion/exclusion criteria may affect the generalizability of
study findings. A pragmatic trial that has less strict inclusion/exclusion criteria, conducted in the
U.S, which enrolls older mRCC patients from the real world clinical practice setting, may provide
a middle ground between RCTs and observational studies. It may also address the issue of
conflicting findings and provide evidence on the effectiveness of CN in the targeted therapy era.
No study to our knowledge has compared healthcare costs between mRCC patients who
received CN+ targeted therapy versus targeted therapy alone. Results from our cost analysis
suggested that patients receiving CN + targeted therapy had similar total healthcare costs to
patients receiving targeted therapy alone. However, they had higher medical costs and lower
prescription costs compared to patients who received targeted therapy alone. Higher medical costs
could be due to the additional cost of CN and morbidity and post-surgical complications associated
with CN.32 Lower prescription drug costs for this group could be due to delayed initiation of
targeted therapy after CN. The average time to receive targeted therapy after CN in our study was
6 months (median was 2.5 months). Although results from our cost analyses were not consistently
robust, all suggested that use of CN did not result in higher total healthcare cost; costs were either
similar or lower than the targeted therapy alone group.
The results of the study should be interpreted in light of several limitations. First, although
we used a propensity score based IPTW method to reduce selection bias, we could not control for
performance status of patients, prognosis, patient and physician preferences or lifestyle factors, all
of which may affect treatment choice and survival outcomes. SEER-Medicare data does not
provide information on performance as measured by the Karnofsky Performance Scale or the
Eastern Cooperative Oncology Group scale.33 However, to reduce the effect of this limitation, we
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measured claims-based performance status from Medicare claims data as suggested by Salloum et
al.34 SEER-Medicare also does not provide information on lab values for hemoglobin, calcium,
neutrophils, and platelets, which are used to assess prognosis using criteria developed by Heng et
al.35 and the Memorial Sloan-Kettering Cancer Center.36 However, we controlled for tumor
characteristics such as tumor grade, site of metastasis, histology, the extent of lymph node
involvement, which are associated with overall survival. Second, registry and administrative
claims data are subject to miscoding errors, which may affect treatment assignment and outcomes
assessed in the study. Claims data is used for reimbursement purposes and may not accurately
reflect patients’ behavior. For example, prescription claims indicate that the prescription was filled
at the pharmacy but do not guarantee actual use by patients. Third, SEER only began collecting
information on metastasis to bone, liver, lung, and brain in 2010. Hence, for patients diagnosed
before 2010, we used ICD9-CM codes to identify sites of metastasis. However, according to the
NCI, this information could be underreported in ICD9-CM codes because physicians are not
required to report site of metastasis to get reimbursed from CMS.37 However, in our study
population, there was a 90% agreement on the site of metastasis reported by SEER after 2010 and
claims-based metastasis for patients diagnosed after 2010. Fourth, this study was conducted among
Medicare patients aged ≥ 65 years at the time of diagnosis and living in SEER areas. Therefore,
findings from this study may not be generalizable to younger mRCC patients or patients living
outside of SEER areas. Fifth, SEER collects cancer stage and tumor-related information only at
the first cancer diagnosis and does not measure disease progression. Therefore, we could not
include patients diagnosed at earlier stages who may have later progressed to stage-IV.
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Conclusions
About one-half of older mRCC patients on Medicare did not receive either CN or targeted
therapy. One-third of patients receiving targeted therapy also underwent CN. In addition to the
clinical factors, a geographical disparity exists in the receipt of CN, which may also affect survival
among patients living in these areas. Our findings, when taken in the context of previously
published studies, suggest that among clinically appropriate mRCC patients CN plays an important
role in extending overall survival. Furthermore, use of CN among targeted therapy users is not
associated with an increase in the lifetime total healthcare costs to Medicare.
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Appendix for study 2
Appendix 3.1 Codes used for identifying targeted therapy and cytoreductive nephrectomy
Drug name
Suntinib

Sorafenib
Pazopanib
Everolimus

Axitinib
Bevacizumab
Temsirolimus
Interferon
alpha
Interleukin

NDC codes (PDE file)
00069055030, 00069055038, 00069077030,
00069077038, 00069083038, 00069098030,
00069098038, 54569598200, 54569598300
00026848858, 50419048858
00173080409, 00078067066
00078056651, 00078056661, 00078056751,
00078056761, 00078059451, 00078059461,
00078062051, 00078062061, 00078041420,
00078041520, 00078041720, 0078062851,
00078062861, 0078062751, 00078062761,
00078062661, 00078062651, 00078041761,
00078041561, 00078041461,
00069014501, 00069015111
50242006001, 50242006101
00008117901, 00008117905
--

HCPCS (Outpatient,
Carrier files)
--

--

----

-J9035, C9257
C9239, J9330
J9212, J9213, J9214,
J9215
J2355, J9015

Appendix 3.2 Codes for cytoreductive nephrectomy
Files
Codes
SEER surgery codes
30, 40, 50, 70, 80
Carrier and outpatient files
50220, 50225, 50230, 50234, 50236, 50240, 50280, 50290,
(HCPCS / CPT codes)
50542, 50543, 50545, 50546, 50548, 50549
Inpatient hospital file (ICD
5501, 554, 5551, 5552, 5553, 5554, 5531, 5539, 5540
9- CM procedure codes)
Appendix 3.3 ICD 9-CM codes for metastasis
Site of metastasis
ICD9-CM codes
Bone
198.5
Brain
198.3, 198.4
Liver
197.7
Lung
197.0, 197.1, 197.2, 197.3
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Appendix 3.4 Adjusted survival curves for CN + targeted therapy vs targeted therapy alone
when survival was measured as a time from treatment initiation until death/end of the study
period
a. Overall Survival

b. Disease-specific survival
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Appendix 3.5 Multivariable Cox proportional hazard model assessing risk of death among
mRCC patients who received CN + targeted therapy versus targeted therapy alone
Hazard Ratio (HR)
Overall survival (n = 561)
Targeted therapy alone
CN + targeted therapy
Disease specific survival (n = 499)
Targeted therapy alone
CN + targeted therapy

95%CI for HR

p-value

Reference
0.37

-0.28 - 0.49

<0.0001

Reference
0.34

-0.25 - 0.46

<0.0001

Note: Covariates included age, gender, race, marital status, zip code level income, zip code level
education, SEER region, urban rural status, NCI comorbidity index, tumor size, tumor grade,
tumor extent (T), lymph node extent (N), cell type, era of diagnosis, metastases to liver /
lung/bone/brain, claims-based performance status

Appendix 3.6 Multivariable generalized linear model assessing total healthcare costs,
medical costs and prescription drug costs mRCC patients who received CN + targeted
therapy versus targeted therapy alone
Average costs per
month

CN + targeted therapy
(n = 154)
Mean (95%CI)

Targeted therapy alone
(n = 326)
Mean (95%CI)

p-value

Total healthcare costs

16,680 (13,578 - 20,491)

22,677 (18,907 - 27,199)

0.0003

Medical costs

14,244 (11,197 - 18,121)

12,992 (9,956 - 16,954)

0.4215

3,318 (2,365 - 4,655)

6,932 (5,208 - 9,229)

<0.0001

Prescription drug costs

Note: Covariates included age, gender, race, marital status, zip code level income, zip code level
education, SEER region, urban rural status, NCI comorbidity index, tumor size, tumor grade,
tumor extent (T), lymph node extent (N), cell type, era of diagnosis, metastases to liver /
lung/bone/brain, claims-based performance status
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Appendix 3.7 Predictors of receiving targeted therapy among older mRCC patients.
Characteristics

Age at diagnosis (years)
- 65-69
- 70-74
- 75-79
- 80 or more
Sex
- Male
- Female
Race/Ethnicity
- White
- Black /others
Marital status
- Married
- Single/Divorced/Separated
Zip code- college educated
- 0 to 15%
- 16-20%
- 21-30%
- 31% and above
Zip code level median
household income (USD)
- < 40k
- 40k - 50 k
- 51k - 70k
- > 70 k
Urban/Rural Status
- Big Metro
- Metro /Urban
- Less urban / Rural
SEER region
- Northeast
- South
- North Central
- West
Year of diagnosis
- 2007 to 2009
- 2010 to 2013
NCI comorbidity index
(mean, SD)
NCI comorbidity index score
-0
-1
-2
- 3 or more

Total
(n = 1,263)
n (%)

Tagreted therapy use

Odds Ratio
(95 % CI)

Yes
(n = 561)

No
(n = 702)

293 (23)
346 (27)
297 (24)
327 (26)

170 (30)
190 (34)
133 (24)
68 (12)

123 (18)
156 (22)
164 (23)
259 (37)

Reference
0.95 (0.68 - 1.35)
0.69 (0.48 - 0.99)*
0.26 (0.18 - 0.39)*

690 (55)
573 (45)

336 (60)
225 (40)

354 (50)
348 (50)

1.12 (0.85 - 1.47)
Reference

1083 (86)
180 (14)

482 (86)
79 (14)

601 (86)
101 (14)

0.84 (0.58 - 1.22)
Reference

610 (48)
653 (52)

316 (56)
245 (44)

294 (42)
408 (58)

1.50 (1.14 - 1.97)*
Reference

366 (29)
217 (17)
279 (22)
401 (32)

147 (26)
94 (17)
121 (22)
199 (35)

219 (31)
123 (18)
158 (23)
202 (29)

Reference
1.31 (0.87 - 1.97)
1.32 (0.87 - 1.99)
1.55 (0.96 - 2.49)

301 (24)
300 (24)
358 (28)
304 (24)

124 (22)
123 (22)
163 (29)
151 (27)

177 (25)
177 (25)
195 (28)
153 (22)

Reference
0.76 (0.51 - 1.14)
0.86 (0.56 - 1.32)
0.91 (0.52 - 1.57)

595 (47)
482 (38)
186 (15)

262 (47)
218 (39)
81 (14)

333 (47)
264 (39)
105 (14)

0.98 (0.62 - 1.53)
0.94 (0.62 - 1.44)
Reference

218 (17)
349 (28)
168 (13)
528 (42)

93 (17)
154 (27)
67 (12)
247 (44)

125 (18)
195 (28)
101 (14)
281 (40)

Reference
1.29 (0.83 - 2.00)
0.98 (0.59 - 1.62)
1.29 (0.89 - 1.87)

525 (42)
738 (58)

206 (37)
355 (63)

319 (45)
383 (55)

Reference
1.48 (1.13 - 1.93)*

1.47 (1.8)

1.21 (1.4)

1.68 (1.9)

0.86 (0.78 - 0.95)*

476 (38)
337 (27)
169 (13)
281 (22)

225 (40)
173 (31)
65 (12)
98 (17)

251 (36)
164 (23)
104 (15)
183 (26)

NA

Note: Odds ratios were calculated from multivariable logistic regression
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Appendix 3.7 Continued
Characteristics
Histology
- Clear cell
- Non clear cell
Tumor size
- Unknown / < 5 cm
- 5 to 7.9 cm
- ≥ 8 cm
Tumor grade
- Well/ moderate
- Poor / undifferentiated
- Unknown
Tumor extent (T) - TNM
- T0 / T1/ unknown
- T2
- T3
- T4
Lymph Node (N) - TNM
- N0 /NX
- N1 /N2
Bone metastasis
- Absent
- Present
Lung metastasis
- Absent
- Present
Liver metastasis
- Absent
- Present
Brain metastasis
- Absent
- Present
Performance status
indicators
Average number of services
- ED visits
- hospital days
- physician claims
- home health claims
DME use (Yes vs No)
Assisting devices (Yes vs No)

Total (n = 1,263)
n (%)

Tagreted therapy use

Odds Ratio
(95 % CI)

Yes

No

1,148 (91)
115 (9)

507 (90)
54 (10)

641 (91)
61 (9)

1.13 (0.73 - 1.74)
Reference

460 (36)
327 (26)
476 (38)

169 (30)
144 (26)
248 (44)

291 (41)
183 (26)
228 (32)

Reference
1.05 (0.74 - 1.47)
1.21 (0.83 - 1.75)

130 (10)
244 (19)
889 (70)

86 (15)
136 (24)
339 (60)

44 (6)
108 (15)
550 (78)

Reference
0.50 (0.30 - 0.83)*
0.42 (0.27 - 0.65)*

603 (48)
183 (15)
359 (28)
118 (9)

217 (39)
91 (16)
201 (36)
52 (9)

386 (55)
92 (13)
158 (23)
66 (9)

Reference
1.21 (0.78 - 1.89)
1.46 (1.03 - 2.08)
1.19 (0.74 - 1.94)

949 (75)
314 (25)

403 (72)
158 (28)

546 (78)
156 (22)

0.77 (0.58 - 1.89)
Reference

750 (59)
513 (41)

327 (58)
234 (42)

423 (60)
279 (40)

Reference
1.22 (0.93 - 1.60)

573 (45)
690 (55)

244 (44)
317 (57)

329 (47)
373 (53)

Reference
0.97 (0.74 - 1.26)

1,004 (79)
259 (21)

465 (83)
96 (17)

529 (77)
163 (23)

Reference
0.65 (0.47 - 0.90)*

1,086 (86)
177 (14)

493 (88)
68 (12)

593 (84)
109 (16)

Reference
0.55 (0.39 - 0.81)*

3.5 (3.2)
1.16 (5.3)
33.2 (30.4)
0.24 (0.8)

4.0 (3.4)
0.53 (2.0)
30.8 (25.0)
0.12 (0.6)

3.1 (2.9)
1.65 (6.9)
35.2 (34.0)
0.33 (0.9)

1.15 (1.10 - 1.21)*
0.94 (0.90 - 0.98)*
1.00 (0.99 - 1.01)
0.76 (0.62 - 0.94)*

487 (39)
240 (19)

199 (35)
96 (17)

288 (41)
144 (21)

0.98 (0.69 - 1.75)
1.15 (0.76 - 1.21)
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Appendix 3.8 Overall survival between mRCC patients that received targeted therapy versus
patients who did not
A) Unadjusted

B) IPTW adjusted method
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Chapter 4
Study 3: Prescribing Patterns of Targeted Therapies, Overall Survival, and Total Healthcare
Cost among Older Adults with Metastatic Renal Cell Carcinoma in the U.S

ABSTRACT
OBJECTIVES
Several targeted therapies have been approved since 2005 to treat metastatic renal cell
carcinoma (mRCC). The first aim of this study was to describe prescribing patterns of targeted
therapies among mRCC patients. The second aim was to describe overall survival (OS) and total
healthcare costs (THC) for commonly observed targeted therapy patterns.
METHODS
This study analyzed 2007-2014 Surveillance Epidemiology and End Result (SEER)Medicare data. Patients with mRCC were defined as those who were diagnosed at stage-IV as well
as those who were diagnosed at earlier stages but were currently using targeted therapies. Further,
we restricted our sample to patients who initiated targeted therapy and were continuously enrolled
in Medicare Fee for Service plans. We described the frequencies of the most commonly used first
and second line targeted therapies for clear-cell and non-clear cell mRCC. We also described the
most frequently used sequences among patients who received two or more lines of targeted
therapies. Oral targeted therapies were identified using generic names and National Drug Codes.
Injectable targeted therapies were identified using the HealthCare Common Procedure Coding
System (HCPCS) codes. Median OS and THC per month were described for the most common
treatment patterns from the date of the first targeted therapy prescription until the end of 2014 or
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until death. Median OS was calculated using Kaplan Meier survival curves. All analyses were
conducted using SAS v.9.4.
RESULTS
Of 915 patients, 521 (57%) used only one line, 240 (26%) used two lines and 154 (17%)
used three or more lines of targeted therapies. Among clear cell mRCC patients, sunitinib (384,
48%) and everolimus (101, 13%) were the most commonly used first and second line targeted
therapies. Of 109 non-clear cell patients, sunitinib (n = 35, 32%) and temsirolimus (n = 26, 24%)
were the most commonly prescribed first line targeted therapies. Only 44 non-clear cell mRCC
patients received second line therapies. Among patients who received multiple lines, VEGFmTOR was the most commonly prescribed sequence. The median OS was 6.0 months, 13.7 months
and 23.7 months for patients with clear cell mRCC who received one line, two lines and 3 or more
lines of targeted therapies respectively. The median monthly THC was significantly higher (p <
0.05) for patients who received only one line of therapy ($ 14,243) than patients who received two
lines ($ 9,985) and three or more lines of therapies ($ 10,110). The median OS and median monthly
THC was similar across targeted therapy sequences.
CONCLUSIONS
About fifty percent of mRCC patients who had at least one targeted therapy received
multiple lines of therapies. Sunitinib and everolimus were the most common first and second line
targeted therapies among mRCC patients. The descriptive analysis suggested that OS and THC
were similar across targeted therapy sequences.
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BACKGROUND
Metastatic renal cell carcinoma (mRCC) is a deadly disease with a 5-year survival rate of
about 12%.1 About 15%-20% of RCC patients are diagnosed at the metastatic stage and about 3033% of patients diagnosed at early stages eventually progress to the metastatic stage. The median
age of RCC diagnosis is 64 years and Medicare covers about 46% of total RCC patients in the
U.S.2, 3
In the last 15 years, systemic therapy has become the main treatment for mRCC patients.
Before 2005, systemic therapy mainly included cytokines such as high dose interleukin-2 and
interferon-alpha. However, both drugs were associated with low tumor response rates, high
toxicity, and improvement of less than 6-12 months in overall survival (OS).4, 5 In 2005, the first
targeted therapy, sorafenib, was approved by the U.S Food and Drug Administration (FDA) to
treat mRCC. Since then, several additional targeted therapies have become available to treat
mRCC.6-10 These include vascular endothelial growth factor inhibitors (VEGFi) like the tyrosine
kinase inhibitors (TKI) sunitinib, pazopanib, and axitinib; the mammalian target of rapamycin
inhibitors (mTORi) everolimus and temsirolimus; and the anti-VEGF monoclonal antibody
bevacizumab. While most of the targeted therapies are approved as first and second line therapies,
everolimus and axitinib are approved only as second-line therapies. Patients treated with first-line
targeted therapy often develop resistance within 6-11 months and as a result, need subsequent lines
of therapy to control disease progression. 6, 8
The availability of several options has complicated decision making regarding the optimal
choice of targeted therapy to treat mRCC patients. The National Comprehensive Cancer Network
(NCCN) develops evidence-based guidelines to help healthcare professionals to decide appropriate
treatment strategies for cancer patients.11,

12

A category-1 recommendation indicates uniform
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consensus about appropriateness of the intervention among NCCN panel members based on a
high-level of evidence; Category-2A indicates uniform consensus based on a lower level of
evidence; category-2B indicates some consensus based on lower level of evidence and category-3
indicates major disagreement about appropriateness of intervention. In the targeted therapy era,
NCCN guidelines included sunitinib, pazopanib, and bevacizumab/interferon as category-1
recommendations and sorafenib as Category-2A recommendation for first-line treatment.
Recommendations for second line therapy included all of the above agents and everolimus.
However, only axitinib and everolimus have a Category-1 recommendation as second-line
treatments while other agents have either category 2-A or 2-B recommendation. No
recommendations were made for the use of third-line targeted therapies.11, 12
Several studies have analyzed prescribing patterns of targeted therapies among mRCC
patients.13-17 Miller et al. (2016) examined targeted therapy patterns using Humana claims data and
assessed their consistency with the NCCN guidelines. They found that the largest proportion of
patients received sunitinib (44%) as first and everolimus (29%) as second-line therapy; both have
category-1 recommendations. Most treatment patterns were consistent with the NCCN
recommendations for first-line therapy, but 5% of patients received everolimus as first-line, nearly
20% received bevacizumab as second line, and 15% received temsirolimus as second-line
therapies.15 These have a lower level of evidence (category 2-B) according to NCCN guidelines.
Bevacizumab is approved by the FDA and recommended to be given in combination with
interferon-α. However, several patients who received bevacizumab did not receive interferon-α.
Similar findings regarding the most common first and second-line treatments were reported by two
other studies.14, 17
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A majority of previously published studies were conducted using commercial claims data
and included patients diagnosed at younger ages. A number of them compared utilization of
individual drug therapies, mainly sunitinib and pazopanib, but few described patterns that covered
the entire therapeutic landscape. Few studies were conducted among older mRCC patient on
Medicare.18 Pal et al. (2017) compared survival among Medicare patients receiving first-line
targeted therapies. The authors found that patients diagnosed in the late-targeted therapy era (20102012) had significantly higher OS than patients from the early- targeted therapy era (2006-2009).
Additionally, patients prescribed pazopanib had higher OS than patients on sunitinib and
sorafenib.20 The study, however, did not describe second or subsequent lines of therapies. Rasca
et al. (2015) compared prescribing patterns and survival among patients from Medicare Advantage
plans. In contrast to Pal et al., no significant difference in OS was observed among sunitinib and
pazopanib users.19 Older adults with mRCC represent a special population for study because they
are under-represented in randomized controlled trials. Additionally, comorbid conditions and
frailty can complicate their treatment and may affect health outcomes. In addition, Medicare is the
single largest payer for RCC patients, covering about 46% of them. The high costs of targeted
therapies, which range from US $6,000 to $15,000 per month and the costs of managing adverse
events and complications, may result in a significant economic burden on Medicare. The first aim
of this study was to describe patterns of first line and subsequent lines of targeted therapies among
older mRCC patients. The second aim was to describe the overall survival and healthcare costs for
the first and the subsequent line targeted therapy users.
METHODS
Data Source

97

SEER-Medicare
We used 2007-2014 SEER-Medicare data. The Patient Entitlement and Diagnosis
Summary File was used to obtain demographics and cancer diagnosis-related information.
Resource use and cost-related information were obtained from Medicare Provider Analysis and
Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies (HHA),
hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used to obtain
inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on hospice
care utilization. The carrier file provided information on non-institutional physician-provided
services whereas the outpatient file provided information on institutional physician-provided
services. The PDE file provided data related to prescription medication use (Medicare Part D).
DME files provided data on the use of durable medical equipment while HHA files were used to
get information on services provided in patients’ homes.20
Study Design and Sample Selection
This was a retrospective cohort study. The study first identified patients with an incident
diagnosis of RCC using the International Classification of Diseases for Oncology, 3rd edition codes
C64.9 and relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318'). Patients who
initiated any systemic therapy between January 2007 and December 2013 were included in the
study. The index date was defined as the date of the first prescription for a newly initiated systemic
therapy. We excluded patients aged < 65 years, diagnosed with another cancer at the time of RCC
diagnosis, diagnosed on autopsy, having cancer reported by death certificate, or enrolled in health
maintenance organizations (HMOs). Figure 1 depicts the sample selection process. Treatment
patterns and overall survival (OS) were measured in the follow-up period, which began after the
index date and continued until death or the end of study period (end of December 2014). Total
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healthcare cost (THC) over the lifetime was assessed among patients that had complete follow up
until death. For cost analyses, patients who were still alive at the end of the study period were
excluded. Baseline characteristics were assessed in the 1-year period prior to the index prescription
date.
Oral targeted therapies were identified using generic names and National Drug Codes
(NDCs) from Medicare Part D. Injectable-targeted therapies were identified using Healthcare
Procedural Codes (HCPC) from Medicare Part B data.
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Figure 4.1 Sample selection process for this study.

SEER-Medicare population
diagnosed with kidney and renal
pelvis cancer from January 2007 to
December 2013
Kidney cancers other than
RCC and patients with
multiple cancers

(n = 57,660)

(n =22,476)

Registry confirmed first primary
RCC diagnosis using ICD-O codes
C.64.9
(n = 35,184)

RCC patients diagnosed at age ≥ 65
years with continuous Medicare
Parts A, B and D enrollment
(n = 6,329)

• Patients aged < 65 years (n =
12,444)
• Diagnosed on autopsy (n = 171)
• Missing date of diagnosis (n =
136)
• Not continuously enrolled in
Medicare Parts A and B (n =
3,317)
• Had HMO coverage (n = 7,073)
• Not continuously enrolled in Part
D prescription drug plan (n =
5,714)
• Patients with no targeted therapy
record (n = 5,336)
• Patients with targeted therapy
use before diagnosis (n = 78)

Cohort of targeted therapy users
after RCC diagnosis
(n = 915)

NOTE: For cost analysis, we excluded an additional 231 patients due to incomplete follow-up
period from index date until death as these patients continued to live beyond December 2014.
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Figure 4.2. Diagrammatic representation of study design
12 months
Baseline period

Follow-up period until death or until the end of study period
Examination of prescribing patterns and survival

Date of first prescription for a targeted
therapy initiation

Study Measures
Prescribing patterns
Prescribing patterns included identification of the most common first line therapies. For
patients who received more than one line, we identified the most common second line therapies.
In addition, the most common treatment sequences were identified. Patterns were assessed
separately for patients who had clear-cell and non-clear cell RCC.
Overall Survival
The study defined overall survival as the time in months from the date of the index
prescription until the date of death or until the end of the study period. Patients that were alive
beyond the follow-up period were censored.
Healthcare cost
Costs were the amounts reimbursed by Medicare for healthcare services. Costs for each
component were calculated and aggregated to calculate total healthcare costs (THC). Costs were
presented as monthly costs. All costs were converted to 2016 US dollars using the Consumer Price
Index for medical care services and medical care commodities.21
Other variables
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These variables included patient demographics, geographical region, tumor characteristics,
site of metastasis, cancer staging specific details, histology, and the National Cancer Institute’s
(NCI) comorbidity index. Information on these variables was obtained in the baseline period.
Statistical Analysis
Sample characteristics were described using basic descriptive statistical procedures. The
median overall survival for the most common treatment patterns and sequences was calculated
using Kaplan Meier curves and Log-rank tests. Healthcare costs were described as mean and
median costs per month. All analyses were conducted at an α level of 0.05 using SAS v.9.4 (SAS
Institute Inc, Cary, NC) and Microsoft Excel 2016.

RESULTS
Sample Characteristics
The final study sample included 915 RCC patients who were prescribed at least one
targeted therapy. About 58% patients were aged between 65-74 years, 61% were males, 85% were
white and 56% were married or lived with a partner. About 47% patients lived in big metropolitan
area, and in the West (47%). About 60% of patients were diagnosed in the later part of the targeted
therapy era (2010-2013). About 68% had one or more comorbidities. A majority of patients were
diagnosed at stage-IV (60%) while 40% were diagnosed at earlier stages. These patients were
assumed to have the recurrent metastatic disease. The vast majority of patients (88%) had clear
cell RCC while only 12% had non-clear cell RCC.
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Table 4.1 Characteristics of older RCC patients who received at least one targeted therapy
Characteristics

Total (n = 915)
Frequency n (%)

Age at diagnosis (years)
- 65-69
- 70-74
- 75-79
- 80 or more
Sex
- Male
- Female
Race/Ethnicity
- White
- Black /others
Marital status
- Married
- Single/Divorced/Separated
Zip code- college educated
- 0 to 15%
- 16-20%
- 21-30%
- 31% and above
Zip code level median household income (USD)
- < 40k
- 40k - 50 k
- 51k - 70k
- > 70 k
Urban/Rural Status
- Big Metro
- Metro /Urban
- Less urban / Rural
SEER region
- Northeast
- South
- North Central
- West
Year of diagnosis
- 2007 to 2009
- 2010 to 2013
NCI comorbidity index score
-0
-1
-2
- 3 or more

264 (29)
264 (29)
214 (23)
173 (19)
560 (61)
355 (39)
778 (85)
137 (15)
515 (56)
400 (44)
260 (29)
146 (16)
184 (20)
325 (36)
206 (23)
187 (20)
276 (30)
246 (27)
431 (47)
350 (38)
134 (15)
156 (17)
229 (25)
104 (11)
426 (47)
367 (40)
548 (60)
350 (38)
262 (29)
121 (13)
182 (20)

Stage at diagnosis
-I
- II
- III
- IV
- Unstaged

111 (12)
36 (4)
175 (19)
553 (60)
40 (4)
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Table 4.1 Continued
Characteristics

Frequency n (%)

Histology
- Clear cell
- Non clear cell
Tumor size
- Unknown / < 5 cm
- 5 to 7.9 cm
- ≥ 8 cm
Tumor grade
- Well/ moderate
- Poor / undifferentiated
- Unknown
Tumor extent (T) - TNM
- T0 / T1/ unknown
- T2
- T3
- T4
Lymph Node (N) - TNM
- N0 /NX
- N1 /N2

806 (88)
109 (12)
290 (32)
250 (27)
375 (41)
211 (23)
305 (33)
399 (44)
351 (38)
128 (14)
375 (41)
61 (7)
721 (79)
194 (21)

Metastasis (M) - TNM
- M0 /MX
- M1

388 (42)
527 (58)

Lines of Therapies
Of 915 patients, 521 (57%) used only one line, 240 (26%) used two lines and 154 (17%)
used three or more lines of therapies. This distribution was similar for clear cell and non-clear
cell RCC patients.
First and second line therapies among clear cell RCC patients
Of 806 clear-cell mRCC patients that received at least one targeted therapy, 384 (48%)
received sunitinib, 139 (17%) received temsirolimus, 128 (16%) received pazopanib, and 71 (9%)
received sorafenib as first-line therapy. A total of 350 patients received 2nd line therapy. Of 2nd line
therapy users, 101 (29%) received everolimus and 84 (24%) patients received temsirolimus.
Approximately equal proportion of patients (10-11%) received sorafenib, sunitinib, and
pazopanib. (Table 2.)
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First and second line therapies among non-clear cell RCC patients
Of 109 non-clear cell patients, sunitinib (n = 35, 32%), temsirolimus (n = 26, 24%), and
bevacizumab (n = 18, 17%) were the most commonly prescribed first line targeted therapies. Only
44 patients received second line therapies. Temsirolimus, sunitinib, and everolimus were the most
common second line therapies (n < 11).
Common sequences of targeted therapies among clear cell RCC patients
Of 350 patients that received two or more lines of therapies, the top five sequences
included: - 1) sunitinib followed by everolimus (8%) 2) sunitinib followed by temsirolimus (6%)
3) sunitinib followed by sorafenib (5%) 4) pazopanib followed by everolimus (4%) and 5) sunitinib
followed by pazopanib (4%). In terms of therapeutic classes, VEGF - mTOR (25%), VEGF-VEGF
(21%), VEGF-mTOR-VEGF (11%), mTOR- VEGF (9%) and VEGF-VEGF-mTOR (6%) were
the most common sequences.
Common sequences of targeted therapies among non-clear cell RCC patients
Only 44 patients received two or more lines of therapies. Temsirolimus followed by
sunitinib (n<11) and temsirolimus followed by bevacizumab (n<11) were the top two sequences.
In terms of therapeutic class, an equal proportion of patients received VEGF-mTOR and mTORVEGF.
Overall Survival (OS)
Median OS by the number of lines of therapies for clear cell and non-clear cell patients is
described in Table 2 and Table 3 respectively. In the descriptive analysis, patients with clear cell
RCC who received two lines of therapies had higher median OS than patients who received only
one line. Similarly, patients who received 3 or more lines had higher OS than patients receiving
one or two lines of targeted therapies. We also examined time since diagnosis for each group to
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understand if there was any survivorship bias. The median time since diagnosis was 121 days for
patients receiving one line of therapy, 106 days for patients receiving two lines, and 118 days for
patients receiving three lines (p= 0.1933) Time since diagnosis also did not differ by number of
line of therapies prescribed for patients that were directly diagnosed at stage-IV and patients
diagnosed at earlier stages.
Kaplan Meier analysis suggested that pazopanib had significantly higher OS than
sorafenib, sunitinib and temsirolimus (p <0.05). Sunitinib followed by pazopanib had a median
OS of 20.7 months compared to 13.7 months for sunitinib followed by everolimus. However, this
difference was not statistically significant. Among patients who received multiple lines of
therapies, no particular drug or a class sequence resulted in a significantly higher OS compared
to other sequences. (Table 4.2)
Among non-clear cell RCC patients, those who received two or more lines of targeted
therapies had higher OS than patients receiving a single line of targeted therapy. However, the
difference in OS was not statistically significant. Time since diagnosis was 166 days for patients
receiving one line of therapy, 112 for patients receiving two lines, and 121 days for patients
receiving three lines (p = 0.3547). Time since diagnosis also did not differ by a number of line of
therapies prescribed for patients that were directly diagnosed at stage-IV and patients diagnosed
at earlier stages. Since very few non-clear cell RCC patients received two or more lines of
therapies, we did not describe OS by drug-level sequencing. In terms of class-level sequence,
patients who received mTOR-VEGF and VEGF-mTOR had similar median OS. (Table 4.3).

106

Table 4.2 Overall survival among clear cell Renal Cell Carcinoma patients receiving
targeted therapy
Median Overall
Survival (months)
Number of lines *
First line only (n = 456)
First and second line (n = 212)
Three or more lines (n = 138)

95%CI

6.0
13.7
23.7

5.0 - 7.0
11.8 - 15.2
20.3 - 26.0

3.9
5.6
9.4
NA
5.2

2.8 - 5.1
2.9 - 6.8
6.6 - 20.8
NA
4.0 -7.1

13.7
11.6
13.9
20.7
13.7

7.6 - 21.2
7.4 - 17.2
7.5 - 22.3
NA
7.1 - 22.4

First line therapy users
• Sunitinib (n = 214)
• Sorafenib (n = 42)
• Pazopanib (n = 65)
• Bevacizumab (n = 50)
• Temsirolimus (n = 74)
Most common drug sequences
• Sunitinib-Everolimus (n = 28)
• Sunitinib-Temsirolimus (n = 20)
• Sunitinib - Sorafenib (n = 19)
• Sunitinib-Pazopanib (n = 14)
• Pazopanib - Everolimus (n = 14)
Most common class sequences

13.9
11.3 - 16.5
• VEGF-mTOR (n = 88)
15.1
11.9 - 18.2
• VEGF-VEGF (n = 73)
18.0
14.4 - 22.7
• VEGF-mTOR-VEGF (n = 39)
10.5
5.4 - 20.4
• mTOR-VEGF (n = 31)
17.8
13.0 - 25.7
• VEGF-VEGF-mTOR (n = 20)
NA: median survival or confidence intervals were not available due to a higher frequency of
censoring.
** Statistically significant, p<0.05
Following comparisons were statistically significant:
First line therapy only: Sunitinib vs pazopanib, sorafenib vs pazopanib, temsirolimus vs
pazopanib
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Table 4.3 Overall survival among non-clear cell Renal Cell Carcinoma patients receiving
targeted therapy
Overall Survival in months
Median

95%CI

Number of lines NS
First line only (n = 65)

6.4

3.9 - 14.1

First and second line (n = 28)

11.6

7.6 - 13.0

Three or more lines (n = 16)

16.3

9.3 - 19.3

5.2
54.6
3.4

2.7 - 11.3
NA
1.3 - 4.2

14.0
10.4

7.6 - 31.3
7.3 - 12.8

First line therapy users
• Sunitinib (n = 25)
• Bevacizumab (n =17)
• Temsirolimus (n = 11)
Most common class sequences
• mTOR-VEGF (n = 12)
• VEGF-mTOR (n<11)

Note: OS is not shown for drug sequences because all had n< 11
NA: median survival or confidence intervals were not available due to a higher frequency of
censoring.
NS: not statistically significant
Total Healthcare Costs
Among clear cell RCC patients, median monthly total healthcare cost was higher among
patients who received only one line of targeted therapy compared to patients who received multiple
lines of therapies. Patients who received two lines and three or more lines of therapies had similar
total healthcare costs. Among patients who received only one line of therapy, the median monthly
total healthcare cost was highest for sunitinib users. Wilcoxon Mann Whitney tests indicated that
median monthly THC for sunitinib users was significantly higher than for bevacizumab,
temsirolimus and pazopanib users (p<0.05). Sorafenib, temsirolimus and pazopanib users had
similar total healthcare costs whereas bevacizumab users had lowest total healthcare costs. For
patients who received two or more sequences, median monthly total healthcare costs were similar
for all the targeted therapy sequences. (Table 4.4)
Among non-clear cell RCC patients, median monthly total healthcare cost was higher
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among patients who received only one line than for patients who received multiple lines of
therapies. No other cost differences were statistically significant.

Table 4.4 Total healthcare costs per month among clear cell Renal Cell Carcinoma patients
receiving targeted therapy
Mean (SD)
US $
Number of lines
• First line only (n = 336)
• First and second line (n = 164)
• Three or more lines (n = 105)
First line therapy users
• Sunitinib (n = 179)
• Temsirolimus (n = 64)
• Sorafenib (n = 38)
• Pazopanib (n = 34)
• Bevacizumab (n = 12)
Most common drug sequences
• Sunitinib-Everolimus (n = 22)
• Sunitinib-Temsirolimus (n = 18)
• Sunitinib - Sorafenib (n = 16)
• Pazopanib - Everolimus (n = <11)
• Sunitinib-Pazopanib (n = <11)
Most common class sequences
• VEGF-mTOR (n = 71)
• VEGF-VEGF (n = 49)
• VEGF-mTOR-VEGF (n = 35)
• mTOR-VEGF (n = 26)
• VEGF-VEGF-mTOR (n = 15)

Median (IQR: Q1 - Q3)
US $

20,837 (20,987)
11,866 (6,785)
10,998 (4,851)

14,243 (8,402 - 25,306)
9,985 (7,579 - 14,080)
10,110 (7,710 - 12,754)

23,750 (21,169)
16,098 (16,605)
21,078 (22,874)
19,696 (27,524)
9,788 (6,032)

16,976 (10,000 - 31,891)
10,592 (6,696 - 19,215)
14,347 (8,776- 19,176)
12,141 (7,751 - 18,382)
9,254 (4,523 - 13,150)

12,237 (7,553)
11,380 (6,008)
9,351 (4,429)
10,243 (2,913)
14,448 (7,157)

10,429 (7,428 - 13,205)
10,712 (8,006 - 12,210)
7,760 (5,960- 13,584)
10,405 (7,749 - 11,952)
12,266 (9,079 - 20,237)

11,516 (6,056)
10,888 (4,925)
11,227 (3,773)
15,519 (9,901)
11,101 (2,748)

10,724 (7,428 - 13,283)
9,481 (7,532 - 13,621)
10,313 (8,782 - 13,665)
12,790 (9,170 - 18,447)
11,598 (9,689 - 12,676)

Note: Significant differences were observed for following comparisons
Number of lines: One line vs two lines: p <.0001, One line vs three or more lines: p <.0001
First line therapy users only: Sunitinib vs pazopanib (p = 0.0293), Sunitinib vs temsirolimus (p =
0.0002), Sunitinib vs bevacizumab (p = 0.0025), Sorafenib vs bevacizumab (p = 0.0332)
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Table 4.5 Total healthcare costs per month among non-clear cell Renal Cell Carcinoma
patients receiving targeted therapy.
Mean (SD)

Median (IQR: Q1 - Q3)

Number of lines NS
•
•
•

23,619 (26,398)
12,490 (5,835)
12,180 (6,470)

14,664 (9,612 - 26,010)
10,403 (7,760 - 17,192)
11,116 (9,766 - 13,790)

First line therapy users
• Sunitinib (n = 20)
• Temsirolimus (n = 11)

32,045(35,942)
18,499 (6,936)

15,144 (9,893 - 40,586)
20,169 (11,002 - 24,262)

Most common class sequences
• mTOR-VEGF (n = <11)
• VEGF-mTOR (n<11)

11,271 (5,862)
14,660 (7,329)

8,011 (7,119 - 17,643)
11,608 (9,826 - 18,450)

First line only (n = 42)
First and second line (n = 23)
Three or more lines (n = 14)

NS: not statistically significant
Note: Significant differences were observed for the following the comparison
Number of lines: One line vs two lines: p = 0.0323
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DISCUSSION
This study examined the prescribing patterns of targeted therapies among older mRCC
patients in the targeted therapy era. To our knowledge, this is the first study which used SEERMedicare data to describe the full spectrum of targeted therapies given over the lifetime of older
mRCC patients. The study assessed the number of lines of targeted therapies, most common first
and second lines and most common sequences prescribed to clear cell and non-clear cell mRCC
patients. In addition, overall survival and total healthcare costs per month from Medicare’s
perspective were described.
The patterns of prescribing for first line treatments, for the most part, were consistent with
the NCCN guidelines. Prescribing patterns in terms of the choice of first and second line therapy
were similar to patterns observed in previous studies.13-15, 17 Some patients in our study received
bevacizumab and sorafenib which have category 2-A recommendations. Among patients who
received a second line therapy, temsirolimus, which has a category 2B recommendation, was given
to 84 (24%) patients. This may be considered a deviation from the NCCN guidelines. A similar
finding was also reported by Miller et al.15 In addition, sorafenib, which has a category-2A
recommendation was less frequently used than temsirolimus. Axitinib, approved in 2012, which
has a category-1 recommendation as a second line therapy was not frequently observed in this
study, probably because the follow-up period ended on December 2014. Additional analysis
among mRCC patients who were diagnosed after 2012 suggested that axitinib use increased in
2013 and 2014.
OS increased with the increase in the number of targeted therapies used among mRCC
patients. The descriptive analysis suggested that pazopanib had higher OS than other targeted
therapies. Pal et al. also assessed SEER-Medicare data and reported that pazopanib had higher OS
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than sunitinib.18 However, Rasca et al. found no difference in OS or risk of death between
pazopanib and sunitinib.19 Our results are primarily descriptive and did not control for prognostic
risk, performance status or sociodemographic factors.
Patients who received multiple lines of therapies had higher OS but OS did not differ across
sequences. Among patients who received two lines, OS was similar between VEGF-mTOR and
VEGF-VEGF classes. Similarly, among patients who received three lines, VEGF-mTOR-VEGF
and VEGF-VEGF-mTOR sequence resulted in a similar OS. Our findings are consistent with
previous studies, which did not find a significant difference in the progression free survival or OS
between targeted therapy sequences.13, 17, 22
The median monthly total healthcare cost was significantly higher for patients who
received only one line of targeted therapy. This could be because patients who received only one
line had more severe or advanced disease or had poorer prognoses, as indicated by their lower OS.
In contrast, patients who received multiple lines could have had better prognoses and performance
status, as suggested by their longer OS. Among patients who used a single line of therapy, median
cost was highest for sunitinib and lowest for bevacizumab. Vogelzang et al. in a recently published
study using Medicare data found that the THC among sunitinib users were higher than pazopanib
users.23 However, McLean et al did not find any significant difference between sunitinib and
pazopanib users.24 Our findings related to sunitinib and sorafenib users were consistent with Kim
et al. who did not find a significant difference between sunitinib and sorafenib users.25 We also
did not find any significant differences across targeted therapy sequences. However, it is important
to note that our cost analyses were descriptive in nature and we did not control for prognosis,
performance status or sociodemographic factors. Also, sample sizes for some drug sequences were
low (n <20).
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This study had several limitations. First, SEER data does not measure cancer recurrence
and progression. Targeted therapies were mainly approved for metastatic RCC, therefore we
assumed that patients who were initially diagnosed at stages-I- III and had a prescription record
for targeted therapy had recurrent metastatic disease. Second, the study could not control for
baseline prognostic risk measured by Heng’s criteria26 or performance status measured by Eastern
Cooperative Oncology Group (ECOG) scale27. This could affect OS and THC. Similarly, the study
did not measure physician and patient preferences, which are important determinants of treatment
selection. Third, this study was conducted among Medicare patients aged ≥ 65 years at the time of
diagnosis and living in SEER areas. Therefore, findings from this study may not be generalizable
to younger mRCC patients or patients living outside of SEER areas. Fourth due to a two year lag
in the availability of the SEER-Medicare data, we could not measure the use of cabozantinib and
nivolumab, which were approved in 2016. Future studies may assess prescribing patterns of
immunotherapies among older adults with mRCC and use data from sources that allow
measurement of risk of prognosis and performance status at the baseline.
Conclusions
Among mRCC patients who received targeted therapies, fifty percent received two or more
lines of targeted therapies. Prescribing patterns of targeted therapies were generally consistent with
NCCN recommendations. OS was significantly higher and THC was significantly lower for
patients who received multiple lines of therapies compared to patients who received a single line.
However, OS and total healthcare costs did not differ significantly by the type of targeted therapy
sequence prescribed.
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Chapter 5: Discussion
Summary of findings
This dissertation focused on three specific issues related to healthcare cost, overall survival
and treatment modalities among older mRCC patients. The first study examined the direct
healthcare cost and the total economic burden of RCC on Medicare. It also examined cost drivers
of total healthcare costs by stage at which RCC was diagnosed. The second study specifically
included RCC patients newly diagnosed at stage-IV (metastatic) and examined the prevalence of
cytoreductive nephrectomy (CN) and targeted therapy use and comparative effectiveness of the
combined use of CN and targeted therapy versus targeted therapy alone strategy. The overall
survival (OS) and total healthcare cost (THC) were the main outcomes. The third study specifically
described the prescribing patterns and sequencing of targeted therapies among mRCC patients and
described the OS and THC among the most common patterns.
Based on our analysis, the economic burden of RCC on Medicare was found to be between
US $1.5 to 2.2 billion, the average THC associated with RCC was $7,419. Based on phase-based
cost approach we found that for patients diagnosed at earlier stages, initial and late phase costs
could be substantially higher than the continuing phase of care. For stage-IV patients though, THC
was higher for all the phases of care due to shorter OS among these patients. This is the first study
in the targeted therapy era, which assessed the healthcare costs by stage at which the RCC was
diagnosed. Our findings suggested that the average THC and the economic burden varied
substantially by the stage at which RCC was diagnosed. Despite of lower prevalence, patients
diagnosed at stage-IV accounted for 50% of total economic burden. Patients diagnosed at stage-I
accounted for the second largest component of the total economic burden. The average THC
associated with stage-IV was 9 times higher than patients diagnosed at stage-I. Study findings
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suggested that hospital costs was the primary drivers of THC for stages I-III whereas prescription
drug cost was the primary drivers of THC among stage-IV patients. According to NCI, a 5-year
survival rate for patients diagnosed at stage-IV is only 12%. Although targeted therapies have
marginally improved OS among stage-IV patients, the unmet needs could be much higher among
stage-IV patients compared to patients diagnosed at earlier stages as the OS is lowest but the
average THC is the highest in this patient group.
Among newly diagnosed mRCC (stage-IV) patients, 29% received targeted therapy alone,
9% received CN alone, and 16% received both CN and targeted therapy. About 47% did not
receive either targeted therapy or CN, which are considered as primary treatments for mRCC.
Prevalence of patients who received targeted therapy or CN in our study was much lower than
previously published studies on commercially insured patients. In addition to factors such as older
age, NCI comorbidity index score, and presence of liver/ brain metastasis, we found that living in
the south and north central region, and rural areas was associated with lower odds for receiving
CN. Results from survival analysis suggested that combined use of CN and targeted therapy played
an important role in improving the OS among mRCC patients. Patients who received CN + targeted
therapy had a lower risk of death and a higher median OS compared to patients that received
targeted therapy alone. These findings, when taken in the context of previously published studies,
suggest that among clinically appropriate mRCC patients CN plays an important role in extending
overall survival. Further, lifetime cost associated with the use of CN+ targeted therapy was similar
to targeted therapy alone group, which suggested that use of CN prior to targeted therapy use may
not increase the monthly THC on Medicare.
Prescribing patterns of targeted therapy among mRCC patients, for the most part, were
consistent with the NCCN guidelines. Findings were also consistent with previous studies in terms
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of drug-level and class level sequencing. About 25% of mRCC patients received temsirolimus as
a second line therapy which can be considered as a deviation from the NCCN guidelines. About
50% of mRCC patients who received targeted therapy, received multiple lines of therapies. This
number may increase in the future with the approval of several targeted / immunotherapies. Results
from the survival analysis suggested that the median OS increased with the addition of an extra
line of treatment. Study findings also suggested that among patients who received two or more
lines of therapies, the OS and median monthly THC was similar across targeted therapy sequences.
However, our findings related to treatment sequencing and OS or THC were descriptive and did
not control for baseline prognosis or performance status.
Implications
Several targeted therapies and immunotherapies are being studied in clinical trials for
mRCC as well as in the adjuvant setting for patients with recurrent disease. Findings from the
economic burden study can be used as a baseline to assess the value of emerging therapies and to
develop key value messages for payers. Interventions that prevent or detect RCC at earlier stages
or manage RCC with fewer complications have the potential to generate cost savings.
Understanding of cost drivers by stage at diagnosis would help Medicare in the allocation of
resources and annual budget planning. Findings related to the association between the combined
use of CN + targeted therapy and OS provided an additional evidence for the potential benefits of
CN in the targeted therapy era. Assessment of predictors for CN or targeted therapy use would
help to identify patients that are good candidates for RCTs and to explore reasons underlying
disparities observed in our study. Findings on prescribing patterns of targeted therapies would be
useful to understand the extent to which targeted therapies were prescribed as per the NCCN
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guidelines. Further, our findings provided real-world evidence on the OS and THC for targeted
therapy sequences among older adults.
Future research
This study assessed the economic burden of RCC using the prevalence-based design.
Future research can be conducted using the incidence-based design to examine healthcare costs
that occur during the lifetime of patients from diagnosis until death. Incidence-based cost studies
may help to better understand healthcare cost during the initial, continuing and terminal phase of
care. Future studies may also assess financial burden to patients and indirect costs to assess the
societal impact of RCC. Our study could not examine the health-related quality of life (HRQoL)
of mRCC patients who received targeted therapy and/or CN. Assessment of HRQoL in addition to
the OS and healthcare cost would help in the complete assessment of the comparative effectiveness
of CN and targeted therapy. Further, it would be interesting to understand the effects of timing and
sequencing of CN and targeted therapy on the overall survival and HRQoL. Also, individually
targeted therapies can be compared in the adjuvant setting (after CN) for their outcomes. Several
studies including ours have assessed the combined use of CN and targeted therapy to targeted
therapy alone. Sunitinib was the commonly assessed targeted therapy in these studies. Other
targeted therapies and immunotherapies can be compared in the adjuvant setting for their effects
on OS, HRQoL, and THC.
From 2016, several immunotherapies such as nivolumab have been approved to treat
mRCC. Combinations of immunotherapies and/or targeted therapies are also being assessed in the
RCTs. Future research may compare new therapies and their combinations among older adults for
their OS, HRQoL, persistence and total healthcare costs. These outcomes can be studied using the
electronic health records in addition to registry and claims data to get the information on laboratory
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values that are used in the Heng’s or MSKCC criteria. This would allow researchers to classify
mRCC patients into risk groups based on their baseline prognosis and to study outcomes stratified
by the baseline risk of prognosis. The landscape of systemic therapies has changed even further
after 2016. As a result, selecting a systemic therapy for the first and subsequent lines has become
more complicated. Future studies may assess prescribing patterns of immunotherapies, patient and
physician-level factors associated with treatment choices and the effects of prescribing patterns on
the health outcomes.
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